INTRODUCTION

[001] The present invention relates to novel therapeutic compounds. More specifically, the present invention relates to novel therapeutic compounds that are inhibitors of epidermal growth factor receptor (EGFR). The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which EGFR activity is implicated including, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer).

BACKGROUND OF THE INVENTION

[002] EGFR (Epidermal Growth Factor Receptor) is a receptor tyrosine kinase in the erbB family (which also includes erbB2, erbB3 and erbB4). It controls a number of downstream signalling pathways in cells by binding a ligand, such as the epidermal growth factor (EGF).

Binding of the ligand induces homodimerisation or heterodimerisation with other family members, which brings about autophosphorylation mediated by the EGFR kinase domain. This process triggers a signal transduction cascade.

[003] EGFR signalling plays a key role in cellular proliferation, survival and suppression of apoptosis. These pathways can become disordered by overexpression or amplification of ligands or receptor, or through genetic alterations in EGFR. Aberrant EGFR signalling can be a key driver for oncogenic transformation, and tumour cell proliferation, invasion and metastasis. As an example, non-small cell lung cancer (NSCLC) patients frequently have activating mutations in EGFR, most commonly an in-frame deletion of Exonl 9, an L858R point mutation and missense mutations in Exon21 (Cancer Discovery, 2016, 6, 601).

[004] Inhibitors of EGFR kinase activity, such as erlotinib, gefitinib, afatinib and osimertinib are effective treatments for EGFR mutated non-small cell lung cancer (Lancet Oncol. 2010, 11, 121; Lancet Oncol. 2016, 17, 577; J. Oncol. Pharm. Pract. 2020, 26, 1452; Lancet Oncol.

2011, 12, 735). Critical to the successful treatment is the selectivity of drugs for the mutated forms of EGFR relative to the wild-type since wild-type inhibition is associated with dose limiting side effects, such as skin rash and diarrhoea.

[005] In almost all patients, treatment with first- and second-generation inhibitors, such as erlotinib, gefitinib and afatinib, leads to drug resistance after an average of 10-12 months (Lancet Oncol. 2010, 1 , 121; Lancet Oncol. 2016 17, 577; Lancet Oncol. 2011, 12, 735). Most commonly, this resistance is due to a secondary mutation in the EGFR kinase domain T790M (J. Thorac. Oncol. 2009, 4, 1), which reduces the receptor’s affinity for first- and second- generation drugs and increases its affinity for ATP (Proc. Natl. Acad. Sci.2008, 105, 2070). [006] Third-generation EGFR inhibitors, such as osimertinib, have been developed to inhibit the T790M mutated forms of EGFR and have been shown to be active in both resistance mutant and activating mutant tumours and have become widely used in both first- and second- line treatment (N. Engl. J. Med.2015, 372, 1689; N. Engl. J. Med.2018, 378, 113). Osimertinib is a covalent inhibitor of EGFR that targets C797 (J. Med. Chem.2014, 57, 8249). Resistance to third-generation therapies such as osimertinib develops with a duration of ca. 10 months. Commonly this resistance is attributable to mutations in the kinase domain that hinder the covalent binding, such as C797S (Brit. J. Cancer 2019, 121, 725). [007] There are no current treatments for cancers that are resistant to third-generation inhibitors. Hence, there is a high unmet need for inhibitors of activated forms of EGFR that harbour mutations, such as C797S that hinder the covalent binding of osimertinib, alongside other mutations such as Exon19Del and L858R, both with and without T790M, but with selectivity over the wild-type form. [008] The present invention was devised with the foregoing in mind. SUMMARY OF THE INVENTION [009] In one aspect, the present invention provides a compound of Formula I as defined herein, and/or a pharmaceutically acceptable salt, hydrate or solvate thereof. [0010] In another aspect, the present invention provides a pharmaceutical composition which comprises a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and one or more pharmaceutically acceptable excipients. [0011] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy. [0012] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition in which EGFR activity is implicated. [0013] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition associated with aberrant activity of EGFR. [0014] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of proliferative disorders (e.g. cancer). [0015] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer. [0016] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a disease or condition in which EGFR activity is implicated. [0017] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a disease or condition associated with aberrant activity of EGFR. [0018] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of proliferative disorders (e.g. cancer or benign neoplasms). [0019] In another aspect, the present invention the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer. [0020] In another aspect, the present invention provides a method of treating a disease or condition in which EGFR activity is implicated, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0021] In another aspect, the present invention provides a method of treating a disease or condition associated with aberrant activity of EGFR, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0022] In another aspect, the present invention provides a method of treating a proliferative disorder (e.g. cancer or benign neoplasms), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0023] In another aspect, the present invention provides a method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0024] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. [0025] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of EGFR positive non-small cell lung cancer. [0026] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [0027] In another aspect, the present invention provides a compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of non- small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [0028] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib. [0029] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of non- small cell lung cancer resistant to treatment with osimertinib. [0030] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. [0031] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of EGFR positive non-small cell lung cancer. [0032] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [0033] In another aspect, the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of non-small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [0034] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib. [0035] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of non-small cell lung cancer resistant to treatment with osimertinib. [0036] In another aspect, the present invention provides a method of treating an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0037] In another aspect, the present invention provides a method of treating EGFR positive non-small cell lung cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0038] In another aspect, the present invention provides a method of treating a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0039] In another aspect, the present invention provides a method of treating non-small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0040] In another aspect, the present invention provides a method of treating a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0041] In another aspect, the present invention provides a method of treating non-small cell lung cancer resistant to treatment with osimertinib, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [0042] In another aspect, the present invention provides a combination treatment comprising a compound of Formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, with one or more additional therapeutic agents. [0043] In another aspect, the present invention provides processes for preparing compounds of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, with one or more additional therapeutic agents. [0044] Preferred, suitable, and optional features of any one particular aspect of the present invention are also preferred, suitable, and optional features of any other aspect. DETAILED DESCRIPTION OF THE INVENTION Definitions [0045] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below. [0046] It is to be appreciated that references to “treating” or “treatment” include prophylaxis as well as the alleviation of established symptoms of a condition. “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms. [0047] A “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated. [0048] The compounds and intermediates described herein may be named according to either the IUPAC (International Union for Pure and Applied Chemistry) or CAS (Chemical Abstracts Service) nomenclature systems. It should be understood that unless expressly stated to the contrary, the terms “compounds of Formula I”, “compounds of the invention” and the more general term “compounds” refer to and include any and all compounds described by and/or with reference to Formula I herein. It should also be understood that these terms encompasses all stereoisomers, i.e. cis and trans isomers, as well as optical isomers, i.e. R and S enantiomers, of such compounds, in substantially pure form and/or any mixtures of the foregoing in any ratio. This understanding extends to pharmaceutical compositions and methods of treatment that employ or comprise one or more compounds of the Formula I, either by themselves or in combination with additional agents. [0049] Unless specified otherwise, atoms are referred to herein by their chemical symbol as appearing in the IUPAC periodic table of the Elements. For example, “C” refers to a carbon atom. [0050] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms. [0051] In this specification the term “alkyl” includes both straight and branched chain alkyl groups. References to individual alkyl groups such as “propyl” are specific for the straight chain version only and references to individual branched chain alkyl groups such as “isopropyl” are specific for the branched chain version only. For Example, “(1-6C)alkyl” includes (1- 4C)alkyl, (1-3C)alkyl, propyl, isopropyl and t-butyl. A similar convention applies to other radicals, for example “phenyl(1-6C)alkyl” includes phenyl(1-4C)alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. [0052] An “alkylene” group is an alkyl group that is positioned between and serves to connect two other chemical groups. Thus, “(1-6C)alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene, ethylene, propylene, 2- methylpropylene, pentylene, and the like. [0053] “(3-6C)cycloalkyl” means a hydrocarbon ring containing from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl. [0054] The term “halo” or “halogeno” refers to fluoro, chloro, bromo and iodo. [0055] As used herein by themselves or in conjunction with another term or terms, “haloalkyl” and “haloalkyl group” refer to alkyl groups in which one or more hydrogen atoms are replaced by halogen atoms. Representative examples include, but are not limited to, –CF ₃ , –CHF ₂ , –CH ₂ F, –CF ₂ CF ₃ , –CHFCF ₃ , and –CH ₂ CF ₃ . Suitably, a haloalkyl group is selected from –CHF ₂ and –CF ₃ , suitably –CF ₃ . [0056] As used herein by themselves or in conjunction with another term or terms, “haloalkoxy” and “haloalkoxy group” refer to alkoxy groups (i.e. O-alkyl groups) in which one or more hydrogen atoms are replaced by halogen atoms. Representative examples include, but are not limited to, –OCF ₃ , –OCHF ₂ , –OCH ₂ F, and –OCF ₂ CF ₃ . Suitably, a haloalkyoxy group is selected from –OCHF ₂ and –OCF ₃ , suitably –OCF ₃ . [0057] The term “heterocyclyl”, “heterocyclic” or “heterocycle” means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as, but not limited to, oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepine. Other heterocycles include dihydrooxathiolyl, tetrahydrooxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO ₂ groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as, but not limited to, tetrahydrothiene 1,1-dioxide and thiomorpholinyl 1,1-dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=O) or thioxo (=S) substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6- dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person would appreciate, any heterocycle may be linked to another group via any suitable atom, such as via a carbon or nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1-yl or morpholin-4-yl ring that is linked via the ring nitrogen. [0058] By “bridged ring systems” is meant ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4 ^th Edition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza- bicyclo[3.2.1]octane and quinuclidine. [0059] By “spiro bicyclic ring systems” we mean that the two ring systems share one common spiro carbon atom, i.e. the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 6- azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptanes, 2-oxa-6- azaspiro[3.3]heptanes, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7- azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane. [0060] The term “heteroaryl” or “heteroaromatic” means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 14, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10- membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five. [0061] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3b]-furanyl-, 2H-furo[3,2b]-pyranyl-, 5H-pyrido[2,3-d]-ooxazinyl-, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5d]thiazolyl, pyrazino[2,3d]pyridazinyl, -imidazo[2,1b]thiazolyl, -imidazo[1,2b][1,2,4]-triazinyl. “Heteroaryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a nonaromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or -sulfur-. Examples of partially aromatic heteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl and 6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazinyl. [0062] Examples of five membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups. [0063] Examples of six membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl. [0064] A bicyclic heteroaryl group may be, for example, a group selected from: a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms; and a cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms. [0065] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl and pyrazolopyridinyl groups. [0066] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolizinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl and pteridinyl groups. [0067] The term “aryl” means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In particular embodiment, an aryl is phenyl. [0068] This specification also makes use of several composite terms to describe groups comprising more than one functionality. Such terms will be understood by a person skilled in the art. For Example heterocyclyl(m-nC)alkyl comprises (m-nC)alkyl substituted by heterocyclyl. [0069] The term “aryl(1-2C)alkyl” means an aryl group covalently attached to a (1-2C)alkylene group, both of which are defined herein. Examples of aryl-(1-2C)alkyl groups include benzyl, phenylethyl, and the like. [0070] “Heteroaryl(1-3C)alkyl” means a heteroaryl group covalently attached to a (1- 3C)alkylene group, both of which are defined herein. Examples of heteroaryl-alkyl groups include pyridin-3-ylmethyl, 2-(benzofuran-2-yl)ethyl, and the like. [0071] “Heterocyclyl(1-2C)alkyl” means a heterocyclyl group covalently attached to a (1- 2C)alkylene group, both of which are defined herein. [0072] “(3-6C)cycloalkyl-(1-2C)alkyl” means a (3-6C)cycloalkyl group covalently attached to a (1-2C)alkylene group, both of which are defined herein. [0073] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. The term “wherein a/any CH, CH ₂ , CH ₃ group or heteroatom (i.e. NH) within a R ¹ group is optionally substituted” suitably means that (any) one of the hydrogen radicals of the R ¹ group is substituted by a relevant stipulated group. [0074] Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. [0075] A wavy bond is used herein to show a point of attachment. [0076] The phrase “compound of the invention” means those compounds which are disclosed herein, both generically and specifically. [0077] As used herein by itself or in conjunction with another term or terms, “pharmaceutically acceptable” refers to materials that are generally chemically and/or physically compatible with other ingredients (such as, for example, with reference to a formulation), and/or are generally physiologically compatible with the recipient (such as, for example, a subject) thereof. [0078] As used herein by themselves or in conjunction with another term or terms, “subject(s)” and “patient(s)”, suitably refer to mammals, in particular humans. Compounds of the invention [0079] In a first aspect, a compound of formula I shown below, or a pharmaceutically acceptable salt thereof:

I wherein: R _N is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, aryl, aryl(1-4C)alkyl, carbon-linked heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups; wherein R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-3C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -O-C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-O- -N(R _NB2 )-C(O)-NR _NB1 -, - SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1- 2C)alkyl, aryl, aryl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, heteroaryl, or heteroaryl(1-4C)alkyl; and wherein Q _N is optionally substituted with one or more R _NC groups; and each R _NC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl, (1-2C)alkoxy, (3-6C)cycloalkyl, -NR _NC1 R _NC2 or -C(O)-R _NC1 , wherein R _NC1 and R _NC2 are each independently hydrogen or (1- 2C)alkyl; R ₁ is selected from hydrogen, (2C)alkynyl, (2C)alkenyl or (1-2C)alkyl; V ₁ is N or C-R ₂ ; R ₂ is hydrogen, halo, cyano, or a group of the formula: -L ₁ -X ₂ -Q ₂ wherein: L ₁ is absent or (1-3C)alkylene; X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -O-C(O)-N(R _3a )-, -N(R _3a )-C(O)-O- -N(R _3b )-C(O)-NR _3a -, -SO ₂ N(R _3a )-, or -N(R _3a )SO ₂ -, where R _3a and R _3b are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl- alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, -NR _3d R _3e , -C(O)-R _3d , -C(O)-OR _3d , -O-C(O)-R _3d , -C(O)-NR _3d R _3e , -N(R _3e )C(O)-R _3d , -S(O) _0-2 R _3d -, -S(O) ₂ NR _3d R _3e , -N(R _3e )-S(O) ₂ R _3d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, or any alkyl, cycloalkyl, or cycloalkyl- alkyl group present in a R _3d or R _3e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1- 2C)alkyl, -OR _3f , -NR _3f R _3g and -C(O)-R _3f , wherein R _3f and R _3g are both independently selected from hydrogen and (1-2C)alkyl; and Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ and R ₆ are each independently selected from hydrogen, halo, cyano, nitro, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- -N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or - N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , -N(R _4e )-S(O) ₂ R _4d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _4d and R _4e are each independently hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _4c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, -OR _4f , -NR _4f R _4g and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, , phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), or (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-OR _5d , -O-C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; R ₇ is selected from hydrogen, halogen, hydroxy, methyl, hydroxymethyl, methoxy, -CF ₃ , -OCF ₃ or cyano; or R ₄ and R ₅ , or R ₅ and R ₆ are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkylalkyl, phenyl, benzyl, heterocyclyl, heterocyclylalkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 4 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that one or two of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -L _2N -X _3N -Q _3N wherein: L _2N is absent or (1-3C)alkylene; X _3N is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )- when L ₂ is absent; or (ii) -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)- N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- - N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ - when L ₂ is (1- 3C)alkylene; wherein R _4a and R _4b are as defined above; Q _3N is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-4C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-6C)alkyl, (3-8C)cycloalkyl, (3- 8C)cycloalkyl(1-4C)alkyl, phenyl, phenyl(1- 4C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L _5aN , X _5aN , L _5bN , and X _5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L _5aN , X _5aN , L _5bN , and X _5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; or R _4N and R _5N , or R _5N and R _6N are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 6; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: R _N and one of R ₄ or R ₅ are optionally linked to form a linker group L. [0080] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof:

I wherein: R _N is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, aryl, aryl(1-4C)alkyl, carbon-linked heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups; wherein R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-3C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -O-C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-O- -N(R _NB2 )-C(O)-NR _NB1 -, - SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1- 2C)alkyl, aryl, aryl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, heteroaryl, or heteroaryl(1-4C)alkyl; and wherein Q _N is optionally substituted with one or more R _NC groups; and each R _NC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl, (1-2C)alkoxy, (3-6C)cycloalkyl, -NR _NC1 R _NC2 or -C(O)-R _NC1 , wherein R _NC1 and R _NC2 are each independently hydrogen or (1- 2C)alkyl; R ₁ is selected from hydrogen, (2C)alkynyl, (2C)alkenyl or (1-2C)alkyl; V ₁ is N or C-R ₂ ; R ₂ is hydrogen, halo, cyano, or a group of the formula: -L ₁ -X ₂ -Q ₂ wherein: L ₁ is absent or (1-3C)alkylene; X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -O-C(O)-N(R _3a )-, -N(R _3a )-C(O)-O- -N(R _3b )-C(O)-NR _3a -, -SO ₂ N(R _3a )-, or -N(R _3a )SO ₂ -, where R _3a and R _3b are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl- alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, -NR _3d R _3e , -C(O)-R _3d , -C(O)-OR _3d , -O-C(O)-R _3d , -C(O)-NR _3d R _3e , -N(R _3e )C(O)-R _3d , -S(O) _0-2 R _3d -, -S(O) ₂ NR _3d R _3e , -N(R _3e )-S(O) ₂ R _3d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, or any alkyl, cycloalkyl, or cycloalkyl- alkyl group present in a R _3d or R _3e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1- 2C)alkyl, -OR _3f , -NR _3f R _3g and -C(O)-R _3f , wherein R _3f and R _3g are both independently selected from hydrogen and (1-2C)alkyl; and Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ , R ₆ and R ₇ are each independently selected from hydrogen, halo, cyano, nitro, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- -N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or - N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, (2-6C)alkenyl, (2- 6C)alkynyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , -N(R _4e )-S(O) ₂ R _4d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _4d and R _4e are each independently hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _4c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, -OR _4f , -NR _4f R _4g , -C(O)OR _4f , -OC(O)R _4f , -C(O)NR _4f R _4g , -NR _4g C(O)R _4f , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, , phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), or (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-OR _5d , -O-C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; or R ₄ and R ₅ , R ₅ and R ₆ , or R ₆ and R ₇ are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkylalkyl, phenyl, benzyl, heterocyclyl, heterocyclylalkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 4 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that one or two of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -L _2N -X _3N -Q _3N wherein: L _2N is absent or (1-3C)alkylene; X _3N is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )- when L ₂ is absent; or (ii) -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)- N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- - N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ - when L ₂ is (1- 3C)alkylene; wherein R _4a and R _4b are as defined above; Q _3N is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-4C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-6C)alkyl, (3-8C)cycloalkyl, (3- 8C)cycloalkyl(1-4C)alkyl, phenyl, phenyl(1- 4C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L _5aN , X _5aN , L _5bN , and X _5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L _5aN , X _5aN , L _5bN , and X _5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; or R _4N and R _5N , or R _5N and R _6N are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 6; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: R _N and one of R ₄ or R ₅ are optionally linked to form a linker group L. [0081] In a particular group of compounds of the invention, R _N is not a directly aryl group that is optionally substituted, i.e. R _N is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3- 8C)cycloalkyl(1-4C)alkyl, aryl(1-4C)alkyl, carbon-linked heterocyclyl, heterocyclyl(1-4C)alkyl, heteroaryl and heteroaryl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups; wherein R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-3C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -O-C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-O-, -N(R _NB2 )-C(O)-NR _NB1 -, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, heteroaryl, or heteroaryl(1-4C)alkyl; and wherein Q _N is optionally substituted with one or more R _NC groups; and each R _NC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl, (1-2C)alkoxy, (3- 6C)cycloalkyl, -NR _NC1 R _NC2 or -C(O)-R _NC1 , wherein R _NC1 and R _NC2 are each independently hydrogen or (1-2C)alkyl. [0082] In a particular group of compounds of the invention, R _N and one of R ₄ or R ₅ are optionally linked to form a linker group L as defined herein. [0083] Particular compounds of the invention include, for example, compounds of the formula I, or pharmaceutically acceptable salts, hydrates and/or solvates thereof, wherein, unless otherwise stated, each of R _N , R _NA , R ₁ , V ₁ , R ₂ , Q ₁ and L each have any of the meanings defined hereinbefore or are as defined in any one of paragraphs (1) to (55) hereinafter:- (1) R _N is selected from hydrogen, (1-5C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl, phenyl(1-4C)alkyl, carbon-linked 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) below; (2) R _N is selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl, phenyl(1-4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, 4- to 6-membered heterocyclyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) below; (3) R _N is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, carbon-linked 5- to 6-membered heterocyclyl, 5- to 6- membered heterocyclyl(1-2C)alkyl, 5- or 6-membered heteroaryl and [5- or 6- membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) below; (4) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -C(O)-O- N(R _NB1 )-, -N(R _NB1 )-C(O)-O- -N(R _NB2 )-C(O)-NR _NB1 -, -SO ₂ N(R _NB1 )- or - N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl; and wherein Q _N is optionally substituted with one or more R _NC groups; and each R _NC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl, (1-2C)alkoxy, (3- 6C)cycloalkyl, -NR _NC1 R _NC2 or -C(O)-R _NC1 , wherein R _NC1 and R _NC2 are each independently hydrogen or (1-2C)alkyl; (5) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -O-C(O)- N(R _NB1 )-, -N(R _NB1 )-C(O)-O- -N(R _NB2 )-C(O)-NR _NB1 -, -SO ₂ N(R _NB1 )- or - N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl; and wherein Q _N is optionally substituted with one or more R _NC groups; and each R _NC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl or (1-2C)alkoxy; (6) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-, -O-C(O)-N(R _NA1 )-, -N(R _NA1 )-C(O)-O-, -N(R _NA2 )-C(O)-NR _NA1 -, -SO ₂ N(R _NA1 )- or -N(R _NA1 )SO ₂ -, where R _NA1 and R _NA2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -O-C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-O- -N(R _NB2 )-C(O)-NR _NB1 -, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl; (7) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )- or -N(R _NA1 )-C(O)-, where R _NA1 is hydrogen or methyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or methyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl; (8) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )- or -N(R _NA1 )-C(O)-, where R _NA1 is hydrogen or methyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or methyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1- 2C)alkyl, 3- to 6-membered heterocyclyl, [3- to 6-membered heterocyclyl](1- 2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1- 2C)alkyl; (9) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )- or -N(R _NA1 )-C(O)-, where R _NA1 is hydrogen or methyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or methyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (3-6C)cycloalkyl, 3- to 6-membered heterocyclyl, [3- to 6- membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6- membered heteroaryl](1-2C)alkyl; (10) R _NA is selected from halo, nitro, cyano, oxo or a group of the formula: -L _NA -X _NA -L _NB -X _NB -Q _N wherein: L _NA is absent or (1-2C)alkylene; X _NA is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NA1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NA1 )- or -N(R _NA1 )-C(O)-, where R _NA1 is hydrogen or methyl; L _NB is absent or (1-4C)alkylene; X _NB is absent or is selected from the group consisting of -O-, -C(O)-, -NR _NB1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _NB1 )-, -N(R _NB1 )-C(O)-, -SO ₂ N(R _NB1 )- or -N(R _NB1 )SO ₂ -, where R _NB1 and R _NB2 are independently selected from the group consisting of hydrogen or methyl; Q _N is selected from the group consisting of hydrogen, (1-6C)alkyl, (2- 6C)alkenyl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl, or [5- or 6- membered heteroaryl](1-2C)alkyl; (11) R ₁ is selected from ethynyl or ethenyl; (12) R ₁ is ethynyl; (13) R ₁ is ethenyl; (14) V ₁ is N; (15) V ₁ is C-R ₂ ; (16) R ₂ is hydrogen, halo, cyano, or a group of the formula -L ₁ -X ₂ -Q ₂ wherein: L ₁ is absent or (1-2C)alkylene; X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -O-C(O)-N(R _3a )-, -N(R _3a )-C(O)-O- -N(R3b)-C(O)-NR _3a -, -SO ₂ N(R _3a )-, or -N(R _3a )SO ₂ -, where R _3a and R3b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 3- to 8- membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6- membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, or (3- 6C)cycloalkyl(1-2C)alkyl, -NR _3d R _3e , -C(O)-R _3d , -C(O)-OR _3d , -O-C(O)-R _3d , - C(O)-NR _3d R _3e , -N(R _3e )C(O)-R _3d , -S(O) _0-2 R _3d -, -S(O) ₂ NR _3d R _3e , - N(R _3e )-S(O) ₂ R _3d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, or any alkyl, cycloalkyl, or cycloalkyl- alkyl group present in a R _3d or R _3e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1- 2C)alkyl, -OR _3f , -NR _3f R _3g and -C(O)-R _3f , wherein R _3f and R _3g are both independently selected from hydrogen and (1-2C)alkyl; (17) R ₂ is hydrogen, halo, cyano, or a group of the formula -L ₁ -X ₂ -Q ₂ wherein: L ₁ is absent or (1-2C)alkylene; X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -SO ₂ N(R _3a )- or -N(R _3a )SO ₂ -, where R _3a is selected from the group consisting of hydrogen or (1- 2C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 3- to 8- membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6- membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, or (3- 6C)cycloalkyl(1-2C)alkyl, -NR _3d R _3e , -C(O)-R _3d , -C(O)-OR _3d , -O-C(O)-R _3d , - C(O)-NR _3d R _3e , -N(R _3e )C(O)-R _3d , -S(O) _0-2 R _3d -, -S(O) ₂ NR _3d R _3e , - N(R _3e )-S(O) ₂ R _3d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen or (1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, or any alkyl group present in a R _3d or R _3e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, or -OR _3f , wherein R _3f is selected from hydrogen and (1-2C)alkyl; (18) R ₂ is hydrogen, cyano, or a group of the formula -L ₁ -X ₂ -Q ₂ wherein: L ₁ is absent or (1-2C)alkylene; X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -SO ₂ N(R _3a )- or -N(R _3a )SO ₂ -, where R _3a is selected from the group consisting of hydrogen or (1- 2C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 4- to 6- membered heterocyclyl, [4- to 6-membered heterocyclyl](1-2C)alkyl, 5- or 6- membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, -NR _3d R _3e , -C(O)-R _3d , - C(O)-OR _3d , -O-C(O)-R _3d , -C(O)-NR _3d R _3e , -N(R _3e )C(O)-R _3d , -S(O) _0-2 R _3d -, -S(O) ₂ NR _3d R _3e , -N(R _3e )-S(O) ₂ R _3d , phenyl, 5 or 6-membered heteroaryl, or 4 to 6- membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen or (1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _3c group is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1- 2C)alkyl, or -OR _3f , wherein R _3f is selected from hydrogen and (1-2C)alkyl; (19) R ₂ is hydrogen, cyano, or a group of the formula -X ₂ -Q ₂ wherein: X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -SO ₂ N(R _3a )- or -N(R _3a )SO ₂ -, where R _3a is selected from the group consisting of hydrogen or (1- 2C)alkyl; Q ₂ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 4- to 6- membered heterocyclyl, [4- to 6-membered heterocyclyl](1-2C)alkyl, 5- or 6- membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, -NR _3d R _3e , phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl, wherein R _3d and R _3e are each independently hydrogen or (1-2C)alkyl; and wherein any alkyl, alkoxy, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, or -OR _3f , wherein R _3f is selected from hydrogen and (1-2C)alkyl; (20) R ₂ is hydrogen, cyano, or a group of the formula -X ₂ -Q ₂ wherein: X ₂ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _3a -, -C(O)-O-, -S(O) _0-2 -, -C(O)-N(R _3a )-, -N(R _3a )-C(O)-, -SO ₂ N(R _3a )- or -N(R _3a )SO ₂ -, where R _3a is selected from the group consisting of hydrogen or methyl; Q ₂ is selected from the group consisting of hydrogen, (1-3C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 4- to 6- membered heterocyclyl, [4- to 6-membered heterocyclyl](1-2C)alkyl, 5- or 6- membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, phenyl, 5 or 6- membered heteroaryl, or 4 to 6-membered heterocyclyl, and wherein any alkyl, alkoxy, phenyl, heteroaryl or heterocyclyl group present in a R _3c group, is optionally further substituted by one or more substituents independently selected from hydroxy or halogen; (21) R ₂ is hydrogen, cyano, or a group of the formula -X ₂ -Q ₂ wherein: X ₂ is absent or is selected from the group consisting of -NR _3a -, -C(O)-O-, -C(O)-N(R _3a )- or -N(R _3a )-C(O)-, where R _3a is selected from the group consisting of hydrogen or methyl; Q ₂ is selected from the group consisting of hydrogen, (1-3C)alkyl, (3- 6C)cycloalkyl, phenyl, phenyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, phenyl, phenylalkyl, heteroaryl or heteroaryl-alkyl in Q ₂ is optionally substituted with one or more R _3c groups; and each R _3c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)alkoxy, or 5 or 6-membered heteroaryl; (22) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ and R ₆ are each independently selected from hydrogen, halo, cyano, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O-, -N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1- 2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-4C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl group present in a R _4c group, or any alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, - OR _4f , -NR _4f R _4g and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, , phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl (including spiro-fused (3- 6C)cycloalkyl), or (3-6C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-OR _5d , -O-C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; R ₇ is selected from hydrogen, halogen, hydroxy, methyl, hydroxymethyl, methoxy, or cyano; or R ₄ and R ₅ , or R ₅ and R ₆ are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; and (iii) 1 to 4 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that one or two of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -L _2N -X _3N -Q _3N wherein: L _2N is absent or (1-3C)alkylene; X _3N is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )- when L ₂ is absent; or (ii) -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)- N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- - N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ - when L ₂ is (1- 3C)alkylene; wherein R _4a and R _4b are as defined above; Q _3N is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, heteroaryl and heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-4C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-6C)alkyl, (3-8C)cycloalkyl, (3- 8C)cycloalkyl(1-4C)alkyl, phenyl, phenyl(1- 4C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L _5aN , X _5aN , L _5bN , and X _5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L _5aN , X _5aN , L _5bN , and X _5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; or R _4N and R _5N , or R _5N and R _6N are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 8-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 5; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: R _N and R ₄ are optionally linked to form a linker group L, as defined in any one of paragraphs (27) to (31) below. (23) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ and R ₆ are each independently selected from hydrogen, halo, cyano, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1- 2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl- alkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-4C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl group present in a R _4c group, or any alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, R _4f , -OR _4f , -NR _4f R _4g and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen or (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, , phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), or (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-OR _5d , -O-C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; R ₇ is selected from hydrogen, hydroxymethyl, or methoxy; or R ₄ and R ₅ , or R ₅ and R ₆ are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -L _2N -X _3N -Q _3N wherein: L _2N is absent or (1-3C)alkylene; X _3N is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )- when L ₂ is absent; or (ii) -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)- N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O- - N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ - when L ₂ is (1- 3C)alkylene; wherein R _4a and R _4b are as defined above; Q _3N is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl(1- 2C)alkyl, heteroaryl and heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L _5aN , X _5aN , L _5bN , and X _5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L _5aN , X _5aN , L _5bN , and X _5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 5; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: R _N and R ₄ are optionally linked to form a linker group L, as defined in any one of paragraphs (27) to (31) below. (24) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ and R ₆ are each independently selected from hydrogen, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6- membered heteroaryl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl, or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-4C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1- 6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; R ₇ is selected from hydrogen, hydroxymethyl, or methoxy; or R ₄ and R ₅ , or R ₅ and R ₆ are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -X _3N -Q _3N wherein: X _3N is absent or is selected from the group consisting of: -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )-; wherein R _4a is as defined above; Q _3N is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heteroaryl and, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: (25) R _N and R ₄ are optionally linked to form a linker group L, as defined in any one of paragraphs (27) to (31) below;Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ and R ₆ are each independently selected from hydrogen, or a group of the formula: -X ₃ -Q ₃ wherein: X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6- membered heteroaryl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -X _5a -L _5b -X _5b -Q ₅ wherein: X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1- 6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; R ₇ is selected from hydrogen, hydroxymethyl, or methoxy; or R ₄ and R ₅ , or R ₅ and R ₆ are linked to form a fused phenyl, 5- or 6- membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from CH ₂ or CHR ₇ ; A ₁₁ is selected from CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or: R _N and R ₄ are optionally linked to form a linker group L, as defined in any one of paragraphs (27) to (31) below. (27) L is a linker group that separates the N atom to which R _N is attached and the carbon atom to which R ₄ is attached by 5, 6 or 7 atoms, or 6, 7 or 8 bond lengths; (28) L is a linker group that separates the N atom to which R _N is attached and the carbon atom to which R ₄ is attached by 5 or 6 atoms, or 6 or 7 bond lengths; (29) L is a linker group of the formula: *-[CR _L1 R _L2 ] _a -X _L -[CR _L3 R _L4 ] _b -; *-[CR _L1 R _L2 ] _c -Q _L -[CR _L3 R _L4 ] _d -X _L -[CR _L1 R _L2 ] _0-2 -; *-Q _L1 -[CR _L3 R _L4 ] _e -X _L -[CR _L1 R _L2 ] _0-2 -; or *-[CR _L3 R _L4 ] _e -Q _L --[CR _L1 R _L2 ] _0-2 -X _L -[CR _L1 R _L2 ] _0-2 -; *-[CR _L1 R _L2 ] _c -X _L -[CR _L3 R _L4 ] _d -X _L1 -[CR _L1 R _L2 ] _0-2 -; wherein: * denotes the point of attachment to the N atom in formula I; R _L1 , R _L2 , R _L3 and R _L4 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl; X _L or X _L1 is absent or selected from -R _L5 C=CR _L6 -, ethynylene, -O-, -N(R _LN )-, -C(O)-N(R _LN )-, -N(R _LN )-C(O)-, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -O-C(O)-N(R _LN )-, - N(R _LN )-C(O)-O-, -N(R _LN1 )-C(O)-N(R _LN )-, -SO ₂ N(R _LN )- or -N(R _LN )SO ₂ -, wherein R _L5 and R _L6 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl, and R _LN and R _LN1 are each independently selected from hydrogen or (1-2C)alkyl; Q _L is selected from a (4-6C)cycloalkyl, a 4 to 7 membered heterocyclyl or a 5 or 6- membered heteroaryl ring; Q _L1 is selected from a (4-6C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring; a is 1-6; b is 0-6; c is 1-6; d is 0-6; and e is 1-6; and wherein Q _L and Q _L1 are optionally substituted by halo, cyan, hydroxy, (1-2C)alkyl, (1- 2C)alkoxy, amino, (1-2C)alkylamino, or [di-(1-2C)alkyl]amino; (30) L is a linker group of the formula: *-[CH ₂ ] _a -X _L -[CH ₂ ] _b -; *-[CH ₂ ] _c -Q _L -[CH ₂ ] _d -X _L -[CH ₂ ] _0-2 -; *-Q _L1 -[CH ₂ ] _e -X _L -[CH ₂ ] _0-2 -; or *-[CH ₂ ] _e -Q _L -[CH ₂ ] _0-2 -X _L -[CH ₂ ] _0-2 -; *-[CH ₂ ] _c -X _L -[CH ₂ ] _d -X _L1 -[CH ₂ ] _0-2 -; wherein: * denotes the point of attachment to the N atom in formula I; X _L or X _L1 is absent or selected from -R _L5 C=CR _L6 -, ethynylene, -O-, -N(R _LN )-, -C(O)-N(R _LN )-, -N(R _LN )-C(O)-, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -O-C(O)-N(R _LN )-, - N(R _LN )-C(O)-O-, -N(R _LN1 )-C(O)-N(R _LN )-, -SO ₂ N(R _LN )- or -N(R _LN )SO ₂ -, wherein R _L5 and R _L6 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl, and R _LN and R _LN1 are each independently selected from hydrogen or (1-2C)alkyl; Q _L is selected from a (4-6C)cycloalkyl, a 4 to 7 membered heterocyclyl or a 5 or 6- membered heteroaryl ring; Q _L1 is selected from a (4-6C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring; a is 1-5; b is 0-3; c is 1-3; d is 0-3; and e is 1-4; and wherein Q _L and Q _L1 are optionally substituted by halo, cyan, hydroxy, (1-2C)alkyl, (1- 2C)alkoxy, amino, (1-2C)alkylamino, or [di-(1-2C)alkyl]amino; (31) L is a linker group of the formula: *-[CH ₂ ] _a -X _L -[CH ₂ ] _b -; *-[CH ₂ ] _c -Q _L -[CH ₂ ] _d -X _L -; *-Q _L1 -[CH ₂ ] _e -X _L -; or *-[CH ₂ ] _e -Q _L -[CH ₂ ] _0-2 -X _L -; *-[CH ₂ ] _c -X _L -[CH ₂ ] _d -X _L1 -[CH ₂ ] _0-2 -; wherein: * denotes the point of attachment to the N atom in formula I; X _L or X _L1 is absent or selected from -R _L5 C=CR _L6 -, ethynylene, -O-, -N(R _LN )-, -C(O)-N(R _LN )-, -N(R _LN )-C(O)-, -S(O) _0-2 -, -SO ₂ N(R _LN )- or -N(R _LN )SO ₂ -, wherein R _L5 and R _L6 are, at each occurrence, independently selected from hydrogen or methyl, and R _LN and R _LN1 are each independently selected from hydrogen or methyl; Q _L is selected from a (5-6C)cycloalkyl, a 5 to 7 membered heterocyclyl or a 5 or 6- membered heteroaryl ring; Q _L1 is selected from a (4-6C)cycloalkyl, a carbon-linked 5 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring; a is 1-2; b is 0-2; c is 1-2; d is 0-2; and e is 1-3; (32) L is a linker group of the formula: *-[CH ₂ ] _a -X _L --[CH ₂ ] _b -; *-[CH ₂ ] _c -Q _L --[CH ₂ ] _d -; *-Q _L1 --[CH ₂ ] _e -; or *-[CH ₂ ] _e -Q _L -; wherein: * denotes the point of attachment to the N atom in formula I; X _L is absent or selected from -R _L5 C=CR _L6 -, -O-, -N(R _LN )-, -C(O)-N(R _LN )- or -N(R _LN )- C(O)-, wherein R _L5 and R _L6 are, at each occurrence, independently selected from hydrogen or methyl, and R _LN and R _LN1 are each independently selected from hydrogen or methyl; Q _L is selected from a (5-6C)cycloalkyl, a 5 to 7 membered heterocyclyl or a 5 or 6- membered heteroaryl ring; Q _L1 is selected from a (4-6C)cycloalkyl, a carbon-linked 5 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring; a is 1-2; b is 0-2; c is 1-2; d is 0-2; and e is 1-3. (33) L is a linker group of the formula: *-CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH=CH-CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -O-CH ₂ - *-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - *-CH ₂ -O-CH ₂ -CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₂ - *-CH ₂ -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -CH ₂ - *-CH ₂ -O-CH ₂ -CH ₂ -CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -O-CH ₂ -O-CH ₂ - *-CH ₂ -O-CH ₂ -CH ₂ -O-CH ₂ - *-CH ₂ -O-CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -O- *-CH ₂ -O-CH ₂ -CH ₂ -CH ₂ -O-CH ₂ - *-CH ₂ -O-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -NH- *-CH ₂ -CH ₂ -CH ₂ -NMe- *-CH ₂ -CH ₂ -NH-CH ₂ - *-CH ₂ -CH ₂ -NHMe-CH ₂ - *-CH ₂ -NH-CH ₂ -CH ₂ - *-CH ₂ -NHMe-CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -NH- *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -NMe- *-CH ₂ -CH ₂ -CH ₂ -NH-CH ₂ - *-CH ₂ -CH ₂ -CH ₂ -NMe-CH ₂ - *-CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -NMe-CH ₂ -CH ₂ - *-CH ₂ -NH-CH ₂ -CH ₂ -CH ₂ - *-CH ₂ -NMe-CH ₂ -CH ₂ -CH ₂ - *-CH ₂ -CH ₂ -CH ₂ -C(O)NH- *-CH ₂ -CH ₂ -CH ₂ -C(O)NMe- *-CH ₂ -CH ₂ -C(O)NH-CH ₂ - *-CH ₂ -CH ₂ -C(O)NMe-CH ₂ - *-CH ₂ -C(O)NH-CH ₂ - CH ₂ - *-CH ₂ -C(O)NMe-CH ₂ -CH ₂ - *-CH ₂ -[cyclopentyl]-CH ₂ -O- *-[cyclopentyl]-[CH ₂ ] _1-2 -O- *-CH ₂ -[cyclopentyl]-CH ₂ -NH- *-[cyclopentyl]-[CH ₂ ] _1-2 -NMe- *-CH ₂ -[5- or 6-membered heteroaryl]-[CH ₂ ] _1-2 -O- *-CH ₂ -[5- or 6-membered heteroaryl]-[CH ₂ ] _1-2 -NH- *-CH ₂ -[5- or 6-membered heteroaryl]-[CH ₂ ] _1-2 -NMe- wherein: * denotes the point of attachment to the N atom in formula I. (34) L is a linker group of the formula: *-CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH=CH-CH ₂ -O- *-CH ₂ -CH ₂ -CH ₂ -CH ₂ -CH ₂ -O- *-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -O- wherein: * denotes the point of attachment to the N atom in formula I. (35) R _N is selected from hydrogen, (1-5C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl(1-4C)alkyl, carbon-linked 3- to 8-membered heterocyclyl, 3- to 8- membered heterocyclyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- or 6- membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (36) R _N is selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl(1-4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, 4- to 6- membered heterocyclyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- or 6- membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (37) R _N is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl(1-2C)alkyl, carbon-linked 5- to 6-membered heterocyclyl, 5- to 6-membered heterocyclyl(1-2C)alkyl, 5- or 6-membered heteroaryl and [5- or 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (38) R _N is selected from hydrogen, (1-5C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl(1-4C)alkyl, carbon-linked 3- to 8-membered heterocyclyl, 3- to 8- membered heterocyclyl(1-4C)alkyl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (39) R _N is selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, phenyl(1-4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, 4- to 6- membered heterocyclyl(1-4C)alkyl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (40) R _N is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl(1-2C)alkyl, carbon-linked 5- to 6-membered heterocyclyl, 5- to 6-membered heterocyclyl(1-2C)alkyl and [5- or 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (41) R _N is selected from hydrogen, (1-5C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, carbon-linked 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyl(1-4C)alkyl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (42) R _N is selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl, 4- to 6-membered heterocyclyl(1-4C)alkyl and [5- or 6-membered heteroaryl](1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (43) R _N is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, carbon- linked 5- to 6-membered heterocyclyl, 5- to 6-membered heterocyclyl(1-2C)alkyl and [5- or 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (44) R _N is selected from hydrogen, (1-5C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, carbon-linked 3- to 8-membered heterocyclyl and 3- to 8-membered heterocyclyl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (45) R _N is selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1- 4C)alkyl, carbon-linked 4- to 6-membered heterocyclyl and 4- to 6-membered heterocyclyl(1-4C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (46) R _N is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, carbon- linked 5- to 6-membered heterocyclyl and 5- to 6-membered heterocyclyl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (47) R _N is selected from (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, carbon-linked 5- to 6-membered heterocyclyl, 5- to 6-membered heterocyclyl(1-2C)alkyl or 5- or 6- membered heteroaryl-(1-2C)alkyl, wherein any cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (48) R _N is selected from (4-6C)cycloalkyl, (4-6C)cycloalkyl-CH ₂ -, 5- to 6-membered heterocyclyl-CH ₂ - or 5- or 6-membered heteroaryl-CH ₂ -, wherein any cycloalkyl, cycloalkyl-CH ₂ -, heterocyclyl-CH ₂ - or heteroaryl-CH ₂ - in R _N is optionally substituted with one or more R _NA groups as defined above or in any one of paragraphs (4) to (10) above; (49) R _N is selected from (4-6C)cycloalkyl, (4-6C)cycloalkyl-CH ₂ -, 5- to 6-membered heterocyclyl-CH ₂ - or 5- or 6-membered heteroaryl-CH ₂ -, wherein a heteroaryl is optionally substituted with (1-3C)alkyl; (50) R _N is selected from: (51) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ , R ₆ and R ₇ are each independently selected from hydrogen, halo, cyano, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1- 2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl- alkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-4C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl group present in a R _4c group, or any alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, R _4f , -OR _4f , -NR _4f R _4g -C(O)OR _4f , -OC(O)R _4f , -C(O)NR _4f R _4g , -NR _4g C(O)R _4f , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen or (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -O-C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-O-, -N(R _5b2 )-C(O)-NR _5b1 -, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, , phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), or (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-OR _5d , -O-C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; or R ₄ and R ₅ , R ₅ and R ₆ , or R ₆ and R ₇ are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -L _2N -X _3N -Q _3N wherein: L _2N is absent or (1-3C)alkylene; X _3N is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )- when L ₂ is absent; or (ii) -O-, -C(O)-, -NR _4a -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)- N(R _4a )-, -N(R _4a )-C(O)-, -O-C(O)-N(R _4a )-, -N(R _4a )-C(O)-O-, -N(R _4b )-C(O)-NR _4a -, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ - when L ₂ is (1- 3C)alkylene; wherein R _4a and R _4b are as defined above; Q _3N is selected from the group consisting of hydrogen, (1-6C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl(1- 2C)alkyl, heteroaryl and heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L _5aN , X _5aN , L _5bN , and X _5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L _5aN , X _5aN , L _5bN , and X _5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 5; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or R _N and R ₄ are linked to form a linker group L as defined herein; (52) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ , R ₆ and R ₇ are each independently selected from hydrogen, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-3C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -S(O) _0-2 -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl, or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-4C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _4c group, or any alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, -OR _4f , -NR _4f R _4g , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -L _5a -X _5a -L _5b -X _5b -Q ₅ wherein: L _5a is absent or (1-3C)alkylene; X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1- 6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; or R ₄ and R ₅ , R ₅ and R ₆ , or R ₆ and R ₇ are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3- 8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from NH, CH ₂ or CHR ₇ ; A ₁₁ is selected from NR _4N , CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from NR _6N , CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _4N and R _6N are each independently selected from hydrogen or a group of the formula: -X _3N -Q _3N wherein: X _3N is absent or is selected from the group consisting of: -C(O)-, -S(O) _0-2 - or -C(O)-N(R _4a )-; wherein R _4a is as defined above; Q _3N is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heteroaryl and, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or R _N and R ₄ are linked to form a linker group L as defined herein; (53) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ , R ₆ and R ₇ are each independently selected from hydrogen, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-2C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, -NR _4d R _4e , -C(O)-R _4d , -C(O)-OR _4d , -O-C(O)-R _4d , -C(O)-NR _4d R _4e , -N(R _4e )C(O)-R _4d , -S(O) _0-2 R _4d - , -S(O) ₂ NR _4d R _4e , or -N(R _4e )-S(O) ₂ R _4d , wherein R _4d and R _4e are each independently hydrogen or (1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _4c group, or any alkyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, -OR _4f , -NR _4f R _4g , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -X _5a -L _5b -X _5b -Q ₅ wherein: X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 -, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ -, where R _5a1 and R _5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1- 6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3- 8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, -NR _5d R _5e , -C(O)-R _5d , -C(O)-NR _5d R _5e , -N(R _5e )C(O)-R _5d , -S(O) _0-2 R _5d -, -S(O) ₂ NR _5d R _5e , -N(R _5e )-S(O) ₂ R _5d , phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl, wherein R _5d and R _5e are each independently hydrogen, (1- 6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R _5d or R _5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R _5f , -OR _5f , -NR _5f R _5g and -C(O)-R _5f , wherein R _5f and R _5g are both independently selected from hydrogen, (1- 4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1- 2C)alkoxy(1-4C)alkyl; or R ₄ and R ₅ , R ₅ and R ₆ , or R ₆ and R ₇ are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1- 2C)haloalkoxy; (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from CH ₂ or CHR ₇ ; A ₁₁ is selected from CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O-, -N(R _5a2 )-C(O)-NR _5a1 -, -SO ₂ N(R _5a1 )- or -N(R _5a1 )SO ₂ - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )-, -N(R _5b1 )-C(O)-, -SO ₂ N(R _5b1 )- or -N(R _5b1 )SO ₂ -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3- 6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1- 2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6- membered heteroaryl(1-2C)alkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or R _N and R ₄ are linked to form a linker group L as defined herein; (54) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: R ₄ , R ₆ and R ₇ are each independently selected from hydrogen, or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-2C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or methyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, methyl, methoxy, (3- 6C)cycloalkyl, -NR _4d R _4e , -C(O)-R _4d or -C(O)-OR _4d , wherein R _4d and R _4e are each independently hydrogen or methyl; and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R _4c group, or any methyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, -OR _4f , -NR _4f R _4g , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is: a) hydrogen, halo, cyano; or b) a group of the formula: -X _5a -L _5b -X _5b -Q ₅ wherein: X _5a is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5a1 - or -N(R _5a1 )-C(O)-, where R _5a1 is independently selected from the group consisting of hydrogen or methyl; L _5b is absent or (1-4C)alkylene; X _5b is absent or is selected from the group consisting of -O-, -C(O)- or -NR _5b1 -, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q ₅ is selected from the group consisting of hydrogen, (1- 6C)alkyl or 3 to 8-membered heterocyclyl and wherein Q ₅ is optionally substituted with one or more R _5c groups; and each R _5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, methyl, methoxy (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: A ₅ is selected from N or CH; A ₆ is selected from N or CR ₄ ; A ₇ is selected from N or CR ₅ ; A ₈ is selected from N or CR ₆ ; A ₉ is selected from N or CR ₇ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; and with the proviso that only one of A ₅ , A ₆ , A ₇ , A ₈ and A ₉ can be N; (iv) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from CH ₂ or CHR ₇ ; A ₁₁ is selected from CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O- or -N(R _5a2 )-C(O)-NR _5a1 - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )- or -N(R _5b1 )-C(O)-, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl or (3-6C)cycloalkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (v) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or R _N and R ₄ are linked to form a linker group L as defined herein; (55) Q ₁ is selected from hydrogen or: (i) a group of the formula: wherein: two of R ₄ , R ₆ and R ₇ are hydrogen, and the other is hydrogen or a group of the formula: -L ₂ -X ₃ -Q ₃ wherein: L ₂ is absent or (1-2C)alkylene; X ₃ is absent or is selected from the group consisting of -O-, -NR _4a -, -C(O)-N(R _4a )-, -N(R _4a )-C(O)-, -SO ₂ N(R _4a )- or -N(R _4a )SO ₂ -, where R _4a and R _4b are independently selected from the group consisting of hydrogen or methyl; Q ₃ is selected from the group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q ₃ is optionally substituted with one or more R _4c groups; and each R _4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, methyl, methoxy, (3- 6C)cycloalkyl, -NR _4d R _4e , -C(O)-R _4d or -C(O)-OR _4d , wherein R _4d and R _4e are each independently hydrogen or methyl; and wherein any methyl, methoxy or cycloalkyl, group present in a R _4c group, or any methyl group present in a R _4d or R _4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, -OR _4f , -NR _4f R _4g , -S(O) _0-2 -R _4f and -C(O)-R _4f , wherein R _4f and R _4g are both independently selected from hydrogen and (1-2C)alkyl; R ₅ is hydrogen or a group of the formula: (ii) a group of the formula: wherein: A ₁ is selected from N, NR _1N , O, S or CR ₇ ; A ₂ is selected from N, NR _1N , O, S or CR ₄ ; A ₃ is selected from N, NR _1N , O, S or CR ₅ ; A ₄ is selected from N, NR _1N , O, S or CR ₇ ; R _1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R _5c groups defined above; R ₄ , R ₅ and R ₇ are as defined above; and with the proviso that: (i) only one of A ₁ , A ₂ , A ₃ and A ₄ can be O or S; (ii) only one of A ₁ , A ₂ , A ₃ and A ₄ can be NR _1N ; (iii) 1 to 3 of A ₁ , A ₂ , A ₃ and A ₄ can be N; (iii) a group of the formula: wherein: p1 is 0 or 1; A ₁₀ is selected from CH ₂ or CHR ₇ ; A ₁₁ is selected from CH ₂ or CHR ₄ ; A ₁₂ is selected from NR _5N , CH ₂ or CHR ₅ ; A ₁₃ is selected from CH ₂ or CHR ₆ ; R ₄ , R ₅ , R ₆ and R ₇ are as defined above; R _5N is: a) hydrogen; b) a group of the formula: -L _5aN -X _5aN -L _5bN -X _5bN -Q _5N wherein: L _5aN is absent or (1-3C)alkylene; X _5aN is absent or is selected from the group consisting of: (i) -C(O)-, -S(O) _0-2 - or -C(O)-N(R _5a1 )- when L _5aN is absent; or (ii) -O-, -C(O)-, -NR _5a1 -, -C(O)-O-, -O-C(O)-, -S(O) _0-2 -, -C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-, -O-C(O)-N(R _5a1 )-, -N(R _5a1 )-C(O)-O- or -N(R _5a2 )-C(O)-NR _5a1 - when L _5aN is present; where R _5a1 and R _5a2 are as defined above; L _5bN is absent or (1-2C)alkylene; X _5bN is absent or is selected from the group consisting of -O-, -C(O)-, -NR _5b1 -, -S(O) _0-2 -, -C(O)-N(R _5b1 )- or -N(R _5b1 )-C(O)-, where R _5b1 and R _5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl; Q _5N is selected from the group consisting of: (i) hydrogen; (ii) (1-4C)alkyl or (3-6C)cycloalkyl; and wherein Q _5N is optionally substituted with one or more R _5c groups as defined above; and with the proviso that one or two of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; (iv) a group of the formula: wherein: p1, A ₁₀ , A ₁₁ , A ₁₂ , and A ₁₃ are as defined above; p2 is 1 to 4; A ₁₄ is C or N; and with the proviso that one of A ₁₀ , A ₁₁ , A ₁₂ and A ₁₃ can be N; or R _N and R ₄ are linked to form a linker group L as defined herein. [0084] Suitably, in any of the definitions of formula I set out herein, a heteroaryl is a 5- or 6- membered heteroaryl ring comprising one, two or three heteroatoms selected from N, O or S. More suitably, in any of the definitions of formula I set out herein, a heteroaryl is a 5- or 6- membered heteroaryl ring comprising one or two N atoms. [0085] Suitably, in any of the definitions of formula I set out herein, a heterocyclyl group is a 4-, 5-, 6- or 7-membered heterocyclyl ring comprising one, two or three heteroatoms selected from N, O or S. Most suitably, a heterocyclyl group is a 4-, 5- or 6-membered ring comprising one or two heteroatoms selected from N, O or S [e.g. morpholinyl (e.g. 4-morpholinyl), piperidinyl, piperazinyl or pyrrolidinyl]. [0086] Suitably, in any of the definitions of formula I set out herein, R _N is as defined in formula I above or is as defined in either of paragraphs (1), (2) or (3) above. In a particular group of compounds of the invention, R _N is as defined in paragraph (1) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (2) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (3) above. [0087] In a particular group of compounds of the invention, R _N is as defined any one of paragraphs (35) to (50) above. In a particular group of compounds of the invention, R _N is as defined in paragraph (35) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (36) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (37) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (38) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (39) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (40) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (41) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (42) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (43) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (44) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (45) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (46) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (47) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (48) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (49) above. In another particular group of compounds of the invention, R _N is as defined in paragraph (50) above. [0088] Suitably, in any of the definitions of formula I set out herein, R _NA is as defined in formula I above or is as defined in either of paragraphs (4), (5), (6), (7), (8), (9) or (10) above. In a particular group of compounds of the invention, R _NA is as defined in paragraph (4) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (5) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (6) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (7) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (8) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (9) above. In another particular group of compounds of the invention, R _NA is as defined in paragraph (10) above. [0089] In a particular group of compounds of the invention, R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above. [0090] In a particular group of compounds of the invention, R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above. [0091] In a particular group of compounds of the invention, R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above. [0092] Suitably, in any of the definitions of formula I set out herein, R ₁ is as defined in formula I above or is as defined in any one of paragraphs (11), (12) or (13) above. In a particular group of compounds of the invention, R ₁ is as defined in paragraph (11) above. In another particular group of compounds of the invention, R ₁ is as defined in paragraph (12) above. In another particular group of compounds of the invention, R ₁ is as defined in paragraph (13) above. [0093] Suitably, in any of the definitions of formula I set out herein, V ₁ is as defined in formula I above or is as defined in any one of paragraphs (14) or (15) above. In a particular group of compounds of the invention, V ₁ is as defined in paragraph (14) above. In another particular group of compounds of the invention, V ₁ is as defined in paragraph (15) above. [0094] Suitably, in any of the definitions of formula I set out herein, R ₂ is as defined in formula I above or is as defined in any one of paragraphs (16), (17), (18), (19), (20), or (21) above. In a particular group of compounds of the invention, R ₂ is as defined in paragraph (16) above. In another particular group of compounds of the invention, R ₂ is as defined in paragraph (17) above. In another particular group of compounds of the invention, R ₂ is as defined in paragraph (18) above. In another particular group of compounds of the invention, R ₂ is as defined in paragraph (19) above. In another particular group of compounds of the invention, R ₂ is as defined in paragraph (20) above. In another particular group of compounds of the invention, R ₂ is as defined in paragraph (21) above. [0095] Suitably, in any of the definitions of formula I set out herein, Q ₁ is as defined in formula I above or is as defined in any one of paragraphs (22), (23), (24) or (25) above. In a particular group of compounds of the invention, Q ₁ is as defined in paragraph (22) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (23) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (24) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (25) above. [0096] Suitably, in any of the definitions of formula I set out herein, Q ₁ is also as defined in formula I above or is as defined in any one of paragraphs (51), (52), (53), (54) or (55) above. In a particular group of compounds of the invention, Q ₁ is as defined in paragraph (51) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (52) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (53) above. In another particular group of compounds of the invention, Q ₁ is as defined in paragraph (54) above. In a particular group of compounds of the invention, Q ₁ is as defined in paragraph (55) above. [0097] Suitably, in any of the definitions of formula I set out herein, L is as defined in formula I above or is as defined in any one of paragraphs (27), (28), (29), (30) or (31) above. In a particular group of compounds of the invention, L is as defined in paragraph (27) above. In another particular group of compounds of the invention, L is as defined in paragraph (28) above. In another particular group of compounds of the invention, L is as defined in paragraph (29) above. In another particular group of compounds of the invention, L is as defined in paragraph (30) above. In another particular group of compounds of the invention, L is as defined in paragraph (31) above. [0098] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [0099] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00100] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00101] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00102] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00103] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00104] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00105] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00106] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00107] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00108] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00109] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00110] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00111] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00112] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00113] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00114] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00115] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00116] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00117] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00118] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00119] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00120] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00121] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00122] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00123] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00124] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00125] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00126] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00127] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00128] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00129] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00130] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00131] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00132] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00133] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00134] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00135] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (17) above; Q ₁ is as defined in paragraph (23) above; and L is as defined in paragraph (29) above. [00136] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00137] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00138] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00139] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00140] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00141] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00142] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00143] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00144] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00145] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00146] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00147] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00148] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00149] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00150] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00151] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00152] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00153] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00154] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00155] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00156] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00157] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00158] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00159] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00160] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00161] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00162] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00163] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00164] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00165] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00166] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00167] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00168] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00169] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00170] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00171] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00172] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00173] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (19) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (31) above. [00174] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00175] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00176] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00177] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00178] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00179] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00180] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00181] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00182] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00183] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00184] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00185] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00186] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00187] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00188] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00189] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00190] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00191] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00192] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00193] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00194] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00195] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00196] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00197] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00198] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00199] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00200] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00201] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00202] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00203] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00204] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00205] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00206] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00207] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00208] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00209] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00210] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (33) above. [00211] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and [00212] L is as defined in paragraph (33) above.In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00213] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00214] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00215] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00216] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00217] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00218] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00219] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00220] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00221] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00222] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00223] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00224] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00225] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00226] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00227] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00228] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00229] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00230] In a particular group of compounds of formula I defined herein: R ₁ and V ₁ are both as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00231] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00232] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00233] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00234] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00235] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00236] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00237] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00238] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00239] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00240] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00241] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00242] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00243] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00244] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00245] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00246] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00247] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00248] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00249] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00250] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00251] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00252] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00253] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00254] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00255] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00256] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00257] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00258] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00259] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00260] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00261] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00262] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00263] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00264] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00265] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00266] In a particular group of compounds of formula I defined herein: V ₁ is as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₁ is as defined in paragraph (11) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00267] In a further group of compounds of formula I defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (51) above. [00268] In a further group of compounds of formula I defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (52) above. [00269] In a further group of compounds of formula I defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (53) above. [00270] In a further group of compounds of formula I defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (54) above. [00271] In a further group of compounds of formula I defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (55) above. [00272] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein in which R ₁ is ethynyl, i.e. the compounds have the formula Ia shown below, or a pharmaceutically acceptable salt thereof: wherein R _N , V ₁ and Q ₁ each have any one of the definitions set out herein. [00273] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00274] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00275] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00276] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00277] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00278] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00279] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00280] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00281] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00282] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00283] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00284] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00285] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00286] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00287] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00288] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00289] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00290] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00291] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00292] In a particular group of compounds of formula Ia: V ₁ is as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00293] In a further group of compounds of formula Ia defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (51) above. [00294] In a further group of compounds of formula Ia defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (52) above. [00295] In a further group of compounds of formula Ia defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (53) above. [00296] In a further group of compounds of formula Ia defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (54) above. [00297] In a further group of compounds of formula Ia defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (55) above. [00298] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein in which R ₁ is ethenyl, i.e. the compounds have the formula Ib shown below, or a pharmaceutically acceptable salt thereof: wherein R _N , V ₁ and Q ₁ each have any one of the definitions set out herein. [00299] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00300] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00301] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00302] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00303] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00304] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00305] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00306] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00307] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00308] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00309] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00310] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00311] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00312] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00313] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00314] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00315] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00316] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00317] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00318] In a particular group of compounds of formula Ib: V ₁ is as defined in formula I above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00319] In a further group of compounds of formula Ib defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (51) above. [00320] In a further group of compounds of formula Ib defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (52) above. [00321] In a further group of compounds of formula Ib defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (53) above. [00322] In a further group of compounds of formula Ib defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (54) above. [00323] In a further group of compounds of formula Ib defined herein: V ₁ , R _N , R _NA , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (55) above. [00324] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein in which V ₁ is C-R ₂ , i.e. the compounds have the formula Ic shown below, or a pharmaceutically acceptable salt thereof: wherein R _N , R ₁ , R ₂ and Q ₁ each have any one of the definitions set out herein. [00325] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00326] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00327] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00328] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (41) above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00329] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (44) above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (16) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00330] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00331] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00332] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00333] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00334] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (18) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00335] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00336] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00337] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00338] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00339] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (20) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00340] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00341] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00342] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00343] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00344] In a particular group of compounds of formula Ic: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₂ is as defined in paragraph (21) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00345] In a further group of compounds of formula Ic defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (51) above. [00346] In a further group of compounds of formula Ic defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (52) above. [00347] In a further group of compounds of formula Ic defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (53) above. [00348] In a further group of compounds of formula Ic defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (54) above. [00349] In a further group of compounds of formula Ic defined herein: V ₁ , R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (55) above. [00350] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein in which V ₁ is N, i.e. the compounds have the formula Id shown below, or a pharmaceutically acceptable salt thereof: wherein R _N , R ₁ and Q ₁ each have any one of the definitions set out herein. [00351] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00352] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00353] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00354] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (41) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00355] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (22) above; and L is as defined in paragraph (28) above. [00356] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00357] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (36) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00358] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (39) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00359] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (42) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00360] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (45) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (24) above; and L is as defined in paragraph (30) above. [00361] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00362] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (37) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00363] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (40) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00364] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (43) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00365] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (46) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (32) above. [00366] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00367] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (47) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00368] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00369] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (49) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00370] In a particular group of compounds of formula Id: R ₁ is as defined in paragraph (11) above; R _N is as defined in paragraph (50) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; Q ₁ is as defined in paragraph (25) above; and L is as defined in paragraph (34) above. [00371] In a further group of compounds of formula Id defined herein: R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (51) above. [00372] In a further group of compounds of formula Id defined herein: R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (52) above. [00373] In a further group of compounds of formula Id defined herein: R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (53) above. [00374] In a further group of compounds of formula Id defined herein: R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (54) above. [00375] In a further group of compounds of formula Id defined herein: R _N , R _NA , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and Q ₁ is as defined in paragraph (55) above. [00376] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein in which R _N and R ₄ are linked to form a Linker group L, i.e. the compounds have the formula Ie shown below, or a pharmaceutically acceptable salt thereof: wherein R ₁ , V ₁ , R ₅ , R ₆ , R ₇ and L each have any one of the definitions set out herein. [00377] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (22) L is as defined in paragraph (27) or (28) above. [00378] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (18) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (23) L is as defined in paragraph (29) above. [00379] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (19) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (24) L is as defined in paragraph (30) above. [00380] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (20) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (24) L is as defined in paragraph (31) above. [00381] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (20) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (25) L is as defined in paragraph (32) above. [00382] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (21) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (26) L is as defined in paragraph (33) above. [00383] In a particular group of compounds of formula Ie: R ₁ is as defined in paragraph (11) above; V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (21) above; and R ₅ , R ₆ and R ₇ are as defined in paragraph (26) L is as defined in paragraph (34) above. [00384] In a further group of compounds of formula Ie defined herein: V ₁ , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and R ₅ , R ₆ and R ₇ are as defined in paragraph (51) above. [00385] In a further group of compounds of formula Ie defined herein: V ₁ , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and R ₅ , R ₆ and R ₇ are as defined in paragraph (52) above. [00386] In a further group of compounds of formula Ie defined herein: V ₁ , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and R ₅ , R ₆ and R ₇ are as defined in paragraph (53) above. [00387] In a further group of compounds of formula Ie defined herein: V ₁ , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and R ₅ , R ₆ and R ₇ are as defined in paragraph (54) above. [00388] In a further group of compounds of formula Ie defined herein: V ₁ , R ₁ , R ₂ and L are as defined in any of the preceding paragraphs; and R ₅ , R ₆ and R ₇ are as defined in paragraph (55) above. [00389] In a particular group of compounds of the invention, the compound is a compound of formula I defined herein having the structural formula If shown below, or a pharmaceutically acceptable salt thereof: wherein R ₁ is ethenyl or ethynyl, V ₁ , R _N , R ₄ and R ₅ , each have any one of the definitions set out herein. [00390] In a particular group of compounds of formula If, R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00391] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (1) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00392] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (2) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00393] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (3) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00394] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (35) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00395] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (38) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00396] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (44) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) and (51) to (55) above. [00397] In a particular group of compounds of formula If, V ₁ is as defined in formula I above; R ₂ is as defined in paragraph (16) above; R _N is as defined in paragraph (48) above and R _NA is as defined in formula I above or is as defined any one of paragraphs (4), (5), (6), (7), (8), (9) or (10) above; R ₄ and R ₅ are as defined in any one of paragraphs (22) to (26) or (51) to (55) above. [00398] Particular compounds of the present invention include any of the compounds described in the example section of the present application, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and, in particular, any of the following: 5-ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]py rimidin-7(8H)-one N-(2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyri do[2,3-d]pyrimidin-5- yl)acrylamide 5-ethynyl-2-((2-methoxyphenyl)amino)-8-methylpyrido[2,3-d]py rimidin-7(8H)-one 8-cyclopentyl-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3 -d]pyrimidin-7(8H)-one 8-(2,4-dimethoxyphenyl)-5-ethynyl-2-((2-methoxyphenyl)amino) pyrido[2,3-d]pyrimidin-7(8H)- one N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyri midin-2-yl)amino)-3- methoxyphenyl)-2-methoxy-N-methylacetamide 5-ethynyl-2-[(2-methoxyphenyl)amino]-N-methyl-7-oxo-8-phenyl pyrido[2,3-d]pyrimidine-6- carboxamide 5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihy dropyrido[2,3-d]pyrimidine-6- carbonitrile 5-ethynyl-2-((2-methoxyphenyl)amino)-N,N,8-trimethyl-7-oxo-7 ,8-dihydropyrido[2,3- d]pyrimidine-6-carboxamide 5-ethynyl-8-isopropyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d ]pyrimidin-7(8H)-one 5-ethynyl-8-(4-methoxyphenyl)-2-((2-methoxyphenyl)amino)pyri do[2,3-d]pyrimidin-7(8H)-one 2-((2-methoxyphenyl)amino)-8-phenyl-5-vinylpyrido[2,3-d]pyri midin-7(8H)-one N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)acetamide N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)methanesulfonamide 2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-5-vinyl-7,8-dihydr opyrido[2,3-d]pyrimidine-6- carbonitrile 8-(2,4-dimethoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpy rido[2,3-d]pyrimidin-7(8H)- one 6-(dimethylamino)-5-ethynyl-2-((2-methoxyphenyl)amino)-8-phe nylpyrido[2,3-d]pyrimidin- 7(8H)-one 8-(2,4-dimethoxyphenyl)-2-((2-methoxyphenyl)amino)-7-oxo-5-v inyl-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile 6-amino-5-ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[ 2,3-d]pyrimidin-7(8H)-one N-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-d ihydropyrido[2,3-d]pyrimidin- 6-yl)acetamide N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)acrylamide 5-ethynyl-8-phenyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8 H)-one 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)am ino)-2-methoxyphenyl)amino)- 5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny l)amino)-5-ethynyl-8-methyl- 6-phenylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny l)amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-benzyl-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-met hoxyphenyl)amino)-5-ethynyl- 8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 4-ethynyl-7-((2-methoxyphenyl)amino)-1-phenylpyrimido[4,5-d] pyrimidin-2(1H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 8-(2-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((2-methoxy-4-morpholinophenyl)amino)-8-phenylpy rido[2,3-d]pyrimidin-7(8H)- one 6-(2-chlorophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)-8-me thylpyrido[2,3-d]pyrimidin- 7(8H)-one 6-(2-chlorophenyl)-2-((2-methoxyphenyl)amino)-8-methyl-5-vin ylpyrido[2,3-d]pyrimidin- 7(8H)-one 2-((2-methoxyphenyl)amino)-8-methyl-6-phenyl-5-vinylpyrido[2 ,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-(phenylamino)pyrido[ 2,3-d]pyrimidin-7(8H)-one 6-(2,6-dichlorophenyl)-2-((2-methoxyphenyl)amino)-8-methyl-5 -vinylpyrido[2,3-d]pyrimidin- 7(8H)-one 6-(2,6-dichlorophenyl)-5-ethynyl-2-((3-(hydroxymethyl)phenyl )amino)-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one 6-(2,6-dichlorophenyl)-2-((3-(hydroxymethyl)phenyl)amino)-8- methyl-5-vinylpyrido[2,3- d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)am ino)phenyl)amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)am ino)phenyl)amino)-8-methyl-5- vinylpyrido[2,3-d]pyrimidin-7(8H)-one 6-benzyl-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl )amino)-8-methyl-5- vinylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2,6-dichlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methy l)amino)phenyl)amino)-8- methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((3-methoxyphenyl)amino)-8-methyl-5-vin ylpyrido[2,3-d]pyrimidin- 7(8H)-one 6-(2-chlorophenyl)-2-((3-(hydroxymethyl)phenyl)amino)-8-meth yl-5-vinylpyrido[2,3- d]pyrimidin-7(8H)-one N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)cyclopropanesulfonamide N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyri midin-2-yl)amino)-3- methoxyphenyl)-3-methoxy-N-methylpropanamide 6-(2-chlorophenyl)-5-ethynyl-2-((2-methoxy-4-(4-methylpipera zin-1-yl)phenyl)amino)-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-5-ethynyl-2-((3-(hydroxymethyl)phenyl)ami no)-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((2-methoxy-4-(4-methylpiperazin-1-yl)p henyl)amino)-8-methyl-5- vinylpyrido[2,3-d]pyrimidin-7(8H)-one N-(2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-5-vinyl-7,8-dih ydropyrido[2,3-d]pyrimidin-6- yl)acetamide 6-(2,6-dichlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methy l)amino)phenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-((4-(4-methylpiperaz in-1-yl)phenyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((4-(2-(dimethylamino)ethoxy)phenyl)ami no)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-5-ethynyl-2-((3-methoxyphenyl)amino)-8-me thylpyrido[2,3-d]pyrimidin- 7(8H)-one 6-(2-chlorophenyl)-8-methyl-2-((4-(4-methylpiperazin-1-yl)ph enyl)amino)-5-vinylpyrido[2,3- d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((4-(2-(dimethylamino)ethoxy)phenyl)ami no)-8-methyl-5-vinylpyrido[2,3- d]pyrimidin-7(8H)-one 2-amino-6-(2-chlorophenyl)-8-methyl-5-vinylpyrido[2,3-d]pyri midin-7(8H)-one 4-ethynyl-7-((2-methoxyphenyl)amino)-1-phenyl-1,6-naphthyrid in-2(1H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-phen ylpyrido[2,3-d]pyrimidin-7(8H)- one (R)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amin o)-5-ethynyl-8-(1- propionylpiperidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-((4-(4-methylpiperaz in-1-yl)butyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-8-methyl-2-((4-(4-methylpiperazin-1-yl)bu tyl)amino)-5-vinylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)pyrido[2,3-d]pyrimidin-7(8H)- one 2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-ethynyl-8-met hylpyrido[2,3-d]pyrimidin- 7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)ami no)-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one N-((1s,4s)-4-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)p henyl)amino)-5-ethynyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-8-((1s,4s)-4- (hydroxymethyl)cyclohexyl)pyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)am ino)-3-methylphenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 8-(2,4-dimethoxyphenyl)-2-((4-((2-(dimethylamino)ethyl)(meth yl)amino)phenyl)amino)-5- ethynylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-3-(1-methyl-1H -pyrazol-4-yl)phenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chloro-5-methoxyphenyl)-2-((4-((2-(dimethylamino)ethyl) (methyl)amino)phenyl)amino)- 5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chloro-5-fluorophenyl)-2-((4-((2-(dimethylamino)ethyl)( methyl)amino)phenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)pyrido[2,3-d]pyrimidin-7(8H)- one 2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-ethynyl-8-phe nylpyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7 (8H)-one 8-(2,4-dimethoxyphenyl)-2-((4-((2-(dimethylamino)ethyl)(meth yl)amino)phenyl)amino)-5- vinylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(2-chloro-3-fluorophenyl)-2-((4-((2-(dimethylamino)ethyl)( methyl)amino)phenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-(4-(dimethylamino)piperidin-1-yl)phenyl)amino)-5-ethyn yl-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-6-(2-methoxyphenyl)- 8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-8-methyl-6- (phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-phenyl-2-((4-(piperazin-1-yl)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one 2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-pheny lpyrido[2,3-d]pyrimidin-7(8H)- one 5-ethynyl-2-((4-(4-isopropylpiperazin-1-yl)phenyl)amino)-8-p henylpyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)ami no)-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino) -8-phenylpyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((4-(1-methylpiperidin-4-yl)phenyl)amino)-8-phen ylpyrido[2,3-d]pyrimidin-7(8H)- one 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-3-methylphenyl )amino)-5-ethynyl-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one 6-(3-chloropyridin-4-yl)-2-((4-((2-(dimethylamino)ethyl)(met hyl)amino)phenyl)amino)-5- ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-(4,7-diazaspiro[2.5]octan-7-yl)phenyl)amino)-5-ethynyl -8-phenylpyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)ami no)-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyr ido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-phenyl-2-((4-(piperidin-4-yl)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)ph enyl)amino)-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-8-phenyl-2-((2,3,4,5-tetrahydro-1H-benzo[d]azepin- 7-yl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(3-methylpiperazin-1-yl)phenyl)amino)-8-phen ylpyrido[2,3-d]pyrimidin-7(8H)- one 8-(3-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((2-methoxyphenyl)amino)-8-(3-nitrophenyl)pyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((2-methoxyphenyl)amino)-8-(4-nitrophenyl)pyrido [2,3-d]pyrimidin-7(8H)-one 8-(3-aminophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-8-phenylpyrido [2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)ph enyl)amino)-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-(3-(hydroxymethyl)azetidin-1-yl)piperidin -1-yl)phenyl)amino)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-(3-fluoro-3-(hydroxymethyl)azetidin-1-yl) piperidin-1-yl)phenyl)amino)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((4-(4-(3-(dimethylamino)azetidin-1-yl)piperidin-1-yl)phen yl)amino)-5-ethynyl-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morph olinophenyl)amino)-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyri midin-2-yl)amino)-2-(4- methylpiperazin-1-yl)phenyl)acetamide N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)propionamide N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)isobutyramide 2-((3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)- yl)phenyl)amino)-2-oxoethyl acetate 8-(4-aminophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)acetamide 2-((4-((3-(Dimethylamino)propyl)(methyl)amino)phenyl)amino)- 5-ethynyl-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 2-((3-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethyny l-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-8-isopropyl-2-((4-(4-methylpiperazin-1-yl)phenyl)a mino)pyrido[2,3-d]pyrimidin- 7(8H)-one 8-cyclopentyl-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)pyrido[2,3-d]pyrimidin- 7(8H)-one N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyri midin-2-yl)amino)-2-(4- methylpiperazin-1-yl)phenyl)propionamide 5-ethynyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-phen ylpyrido[2,3-d]pyrimidin-7(8H)- one 5-ethynyl-2-((4-morpholinophenyl)amino)-8-phenylpyrido[2,3-d ]pyrimidin-7(8H)-one N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)methanesulfonamide N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)cyclopropanecarboxamide 5-ethynyl-2-((4-(4-(3-(methoxymethyl)azetidin-1-yl)piperidin -1-yl)phenyl)amino)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one N-((1r,4r)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide 2-((4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)- yl)phenyl)amino)-2-oxoethyl acetate N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)acrylamide 8-(4-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido [2,3-d]pyrimidin-7(8H)-one 6-cyclopropyl-5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1- yl)phenyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-6,8-dimethyl-2-((4-(4-methylpiperazin-1-yl)phenyl) amino)pyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((4-(4-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)pi peridin-1-yl)phenyl)amino)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one 2-((3-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5 -ethynyl-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d ]pyrimidin-8(7H)- yl)phenyl)propionamide 5-ethynyl-2-((2-(hydroxymethyl)phenyl)amino)-8-phenylpyrido[ 2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)-6-(thiophen-2-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 2-(dimethylamino)-N-(3-((5-ethynyl-8-methyl-7-oxo-7,8-dihydr opyrido[2,3-d]pyrimidin-2- yl)amino)phenyl)-N-methylacetamide N-((1r,4r)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)pyridazine-4-carboxamide 2-(dimethylamino)-N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydr opyrido[2,3-d]pyrimidin-2- yl)amino)-3-methoxyphenyl)acetamide 4-(((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)amino)-4-oxobutanoic acid N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-N4,N4-dimethylsuccinamide N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-N3-methylmalonamide N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-N3,N3-dimethylmalonamide 3-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpip erazin-1-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)propanamide 4-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpip erazin-1-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)butanamide N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-N4-methylsuccinamide 3-(((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)pheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)amino)-3-oxopropanoic acid 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpip erazin-1-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)-8-phenylpyrido[2,3- d]pyrimidin-7(8H)-one 8-(cyclopentylmethyl)-5-ethynyl-2-((4-(4-methylpiperazin-1-y l)phenyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((1'-methyl-[1,4'-bipiperidin]-4-yl)amino)-8-phe nylpyrido[2,3-d]pyrimidin-7(8H)- one 8-cyclohexyl-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl) amino)pyrido[2,3-d]pyrimidin- 7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(tet rahydro-2H-pyran-4- yl)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((te trahydrofuran-3- yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one (S)-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8- ((5-oxopyrrolidin-2- yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((te trahydrofuran-2- yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl )amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-2-(1H-pyrazol-4-yl)acetamid e 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((2-methoxypheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide 5-ethynyl-8-(2-hydroxycyclopentyl)-2-((4-(4-methylpiperazin- 1-yl)phenyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((2-methoxypheny l)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)cyclohexyl)-N-methylacetamide N-((1r,4r)-4-(5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1- yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide N-((1s,4s)-4-(5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1- yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(2-o xopyrrolidin-3-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(tet rahydrofuran-3-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(pyr rolidin-3-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(1-m ethylpyrrolidin-3-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(5-o xopyrrolidin-3-yl)pyrido[2,3- d]pyrimidin-7(8H)-one 8-((1H-pyrazol-5-yl)methyl)-5-ethynyl-6-methyl-2-((4-(4-meth ylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-6-methyl-8-((1-methyl-1H-pyrazol-3-yl)methyl)-2-(( 4-(4-methylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 8-((1H-imidazol-5-yl)methyl)-5-ethynyl-6-methyl-2-((4-(4-met hylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-6-methyl-8-((1-methyl-1H-pyrazol-5-yl)methyl)-2-(( 4-(4-methylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-(isoxazol-5-ylmethyl)-6-methyl-2-((4-(4-methylpi perazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)-8-(pyridin-3- ylmethyl)pyrido[2,3-d]pyrimidin-7(8H)-one 8-(cyclopentylmethyl)-5-ethynyl-6-methyl-2-((4-(4-methylpipe razin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-(1-methyl-5-oxopyrrolidin-3-yl)-2-((4-(4-methylp iperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-8-((1-methyl-1H-pyrazol-3-yl)methyl)-2-((4-(4-meth ylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amin o)-8-(oxazol-2- ylmethyl)pyrido[2,3-d]pyrimidin-7(8H)-one 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((2- oxopyrrolidin-3- yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one 1 ⁵ -ethynyl-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacycloheptaphan-1 ⁷ -one (Z)-1 ⁵ -ethynyl-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacyclooctaphan-6-en-1 ⁷ -one (Z)-1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-6-en-1 ⁷ -one 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amin o}-8-(1,2-oxazol-4- ylmethyl)pyrido[2,3-d]pyrimidin-7-one; 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amin o}-8-(1,3-oxazol-5- ylmethyl)pyrido[2,3-d]pyrimidin-7-one; 5-Ethynyl-8-(1H-imidazol-2-ylmethyl)-6-methyl-2-{[4-(4-methy lpiperazin-1- yl)phenyl]amino}pyrido[2,3-d]pyrimidin-7-one; 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amin o}-8-(pyridin-2- ylmethyl)pyrido[2,3-d]pyrimidin-7-one; 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amin o}-8-(pyridin-4- ylmethyl)pyrido[2,3-d]pyrimidin-7-one; 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amin o}-8-[(1-methylpyrazol-4- yl)methyl]pyrido[2,3-d]pyrimidin-7-one; 8-Cyclopentyl-5-ethynyl-2-[(3-([3-(methanesulfonylmethyl)aze tidin-1- yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one; 8-Cyclopentyl-5-ethynyl-2-[(3-([3-(methanesulfonylmethyl)pyr rolidin-1- yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one; 8-Cyclopentyl-5-ethynyl-2-[(3-([4-(methanesulfonylmethyl)pip eridin-1- yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one; 8-Cyclopentyl-5-ethynyl-2-[(2-methyl-1,3-dihydroisoindol-4-y l)amino]pyrido[2,3-d]pyrimidin-7- one; 8-Cyclopentyl-5-ethynyl-2-[(2-methyl-3,4-dihydro-1H-isoquino lin-5-yl)amino]pyrido[2,3- d]pyrimidin-7-one; (Z)-1 ⁵ -ethynyl-1 ⁶ -methyl-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacyclooctaphan-6-en-1 ⁷ -one; 1 ⁵ -ethynyl-1 ⁶ -methyl-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacyclooctaphan-1 ⁷ -one; (5 ¹ R,5 ³ S)-3 ⁵ -ethynyl-3 ⁷ ,3 ⁸ -dihydro-7-oxa-2-aza-3(2,8)-pyrido[2,3-d]pyrimidina-1( 1,3)- benzena-5(1,3)-cyclopentanacycloheptaphan-3 ⁷ -one; 1 ⁵ -Ethynyl-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -Ethynyl-1 ⁶ -methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; (Z)-1 ⁵ -ethynyl-1 ⁷ ,1 ⁸ -dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3( 1,3)- benzenacyclononaphan-7-en-1 ⁷ -one; 1 ⁵ -Ethynyl-34-(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -Ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,6-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; 1 ⁵ -Ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -Ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -Ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one; N-(5-((5-ethynyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-y l)amino)-2-(4-methylpiperazin-1- yl)benzyl)acrylamide; 8-cyclopentyl-5-ethynyl-2-((2-(3-((methylsulfonyl)methyl)pip eridin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1s,3s)-3- ((methylsulfonyl)methyl)cyclobutyl)amino)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one; 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1s,4s)-4- ((methylsulfonyl)methyl)cyclohexyl)amino)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one; 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1r,3r)-3- ((methylsulfonyl)methyl)cyclobutyl)amino)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one; 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1r,4r)-4- ((methylsulfonyl)methyl)cyclohexyl)amino)phenyl)amino)pyrido [2,3-d]pyrimidin-7(8H)-one; 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)-3-propoxyp henyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one; 5-ethynyl-2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)ami no)-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one; 2-((3-(2-cyclopentylethoxy)-4-(4-methylpiperazin-1-yl)phenyl )amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one; 2-((3-(2-cyclopentylethoxy)-4-(4-methylpiperazin-1-yl)phenyl )amino)-5-ethynyl-8-((1-methyl- 1H-pyrazol-3-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one; 2-((3-(cyclopentylmethoxy)-4-(4-methylpiperazin-1-yl)phenyl) amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one; 2-((3-(3-cyclopentylpropoxy)-4-(4-methylpiperazin-1-yl)pheny l)amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one; 2-((3-(2-cyclohexylethoxy)-4-(4-methylpiperazin-1-yl)phenyl) amino)-5-ethynyl-8- methylpyrido[2,3-d]pyrimidin-7(8H)-one; 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)-3-phenetho xyphenyl)amino)pyrido[2,3- d]pyrimidin-7(8H)-one; 2-((3-(cyclopentyloxy)-4-(4-methylpiperazin-1-yl)phenyl)amin o)-5-ethynyl-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one; 5-ethynyl-2-((3-(isopentyloxy)-4-(4-methylpiperazin-1-yl)phe nyl)amino)-8-methylpyrido[2,3- d]pyrimidin-7(8H)-one; 2-cyclopentyl-N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyr ido[2,3-d]pyrimidin-2-yl)amino)- 2-(4-methylpiperazin-1-yl)phenyl)acetamide; N-(cyclopentylmethyl)-5-((5-ethynyl-8-methyl-7-oxo-7,8-dihyd ropyrido[2,3-d]pyrimidin-2- yl)amino)-2-(4-methylpiperazin-1-yl)benzenesulfonamide; 1-cyclopentyl-3-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyr ido[2,3-d]pyrimidin-2-yl)amino)- 2-(4-methylpiperazin-1-yl)phenyl)urea; 5-ethynyl-8-methyl-2-((3-(2-(1-methyl-1H-pyrazol-3-yl)ethoxy )-4-(4-methylpiperazin-1- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; N-(cyclopentylmethyl)-5-((5-ethynyl-8-methyl-7-oxo-7,8-dihyd ropyrido[2,3-d]pyrimidin-2- yl)amino)-2-(4-methylpiperazin-1-yl)benzamide; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; 1 ⁵ -ethynyl-5-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,5-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphane-1 ⁷ ,6-dione; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphane-1 ⁷ ,4-dione; 1 ⁵ -ethynyl-4-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; 1 ⁵ -ethynyl-5-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,5-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,6-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclooctaphane-1 ⁷ ,7-dione; 1 ⁵ -ethynyl-9-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclononaphan-1 ⁷ -one; 1 ⁵ -ethynyl-16-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclononaphan-1 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclodecaphan-1 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclononaphan-1 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4,7-dioxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclononaphan-1 ⁷ -one; (5 ¹ S,5 ³ R)-3 ⁵ -ethynyl-1 ⁴ -(4-methylpiperazin-1-yl)-3 ⁷ ,3 ⁸ -dihydro-7-oxa-2-aza-3(2,8)-pyrido[2,3- d]pyrimidina-1(1,3)-benzena-5(1,3)-cyclopentanacycloheptapha n-3 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-thia-2,5-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one 4,4-dioxide; 1 ⁵ -ethynyl-3 ⁴ -(4-isopropylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; 1 ⁵ -ethynyl-3 ⁴ -(4-(2-methoxyethyl)piperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina- 3(1,3)-benzenacyclononaphane-1 ⁷ ,6-dione; 1 ⁵ -ethynyl-3 ⁴ -(4-methyl-1,4-diazepan-1-yl)-1 ⁷ ,1 ⁸ -dihydro-2,4-diaza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphane-1 ⁷ ,5-dione; (R)-1 ⁵ -ethynyl-8-methyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)- pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; 1 ⁵ -ethynyl-3 ⁴ -(4-methylpiperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-6-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one; and 1 ⁵ -ethynyl-3 ⁴ -(4-(2-methoxyethyl)piperazin-1-yl)-1 ⁷ ,1 ⁸ -dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3- d]pyrimidina-3(1,3)-benzenacyclooctaphan-1 ⁷ -one. [00399] Though the present invention may relate to any compound or particular group of compounds defined herein by way of optional, preferred or suitable features or otherwise in terms of particular embodiments, the present invention may also relate to any compound or particular group of compounds that specifically excludes said optional, preferred or suitable features or particular embodiments. [00400] Suitably, the present invention excludes any individual compounds not possessing the biological activity defined herein. Salts and Solvates [00401] The compounds (including final products and intermediates) described herein may be isolated and used per se or may be isolated in the form of a salt, suitably pharmaceutically acceptable salts. It should be understood that the terms “salt(s)” and “salt form(s)” used by themselves or in conjunction with another term or terms encompasses all inorganic and organic salts, including industrially acceptable salts, as defined herein, and pharmaceutically acceptable salts, as defined herein, unless otherwise specified. As used herein, industrially acceptable salts are salts that are generally suitable for manufacturing and/or processing (including purification) as well as for shipping and storage, but may not be salts that are typically administered for clinical or therapeutic use. Industrially acceptable salts may be prepared on a laboratory scale, i.e. multi-gram or smaller, or on a larger scale, i.e. up to and including a kilogram or more. [00402] Pharmaceutically acceptable salts, as used herein, are salts that are generally chemically and/or physically compatible with the other ingredients comprising a formulation, and/or are generally physiologically compatible with the recipient thereof. Pharmaceutically acceptable salts may be prepared on a laboratory scale, i.e. multi-gram or smaller, or on a larger scale, i.e. up to and including a kilogram or more. It should be understood that pharmaceutically acceptable salts are not limited to salts that are typically administered or approved by the FDA or equivalent foreign regulatory body for clinical or therapeutic use in humans. A practitioner of ordinary skill will readily appreciate that some salts are both industrially acceptable as well as pharmaceutically acceptable salts. It should be understood that all such salts, including mixed salt forms, are within the scope of the application. [00403] In one embodiment, the compounds of Formula I and sub-formulae thereof are isolated as pharmaceutically acceptable salts. [00404] A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. [00405] In general, salts of the present application can be prepared in situ during the isolation and/or purification of a compound (including intermediates), or by separately reacting the compound (or intermediate) with a suitable organic or inorganic acid or base (as appropriate) and isolating the salt thus formed. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised. In practice, the various salts may be precipitated (with or without the addition of one or more co-solvents and/or anti-solvents) and collected by filtration or the salts may be recovered by evaporation of solvent(s). Salts of the present application may also be formed via a “salt switch” or ion exchange/double displacement reaction, i.e. reaction in which one ion is replaced (wholly or in part) with another ion having the same charge. One skilled in the art will appreciate that the salts may be prepared and/or isolated using a single method or a combination of methods. [00406] Representative salts include, but are not limited to, acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate, trifluoroacetate and the like. Other examples of representative salts include alkali or alkaline earth metal cations such as, but not limited to, sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, lysine, arginine, benzathine, choline, tromethamine, diolamine, glycine, meglumine, olamine and the like. [00407] Certain compounds of the Formula I and sub-formulae thereof may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms that possess the biological activity described herein. Polymorphs [00408] It is also to be understood that certain compounds of the Formula I and sub-formulae thereof may exhibit polymorphism, and that the invention encompasses all such forms that possess the biological activity described herein. N-oxides [00409] Compounds of the Formula I and sub-formulae thereof containing an amine function may also form N-oxides. A reference herein to a compound of the Formula I and sub-formulae thereof that contains an amine function also includes the N-oxide. Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidised to form an N-oxide. Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle. N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as, but not limited to, hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4 ^th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as, but not limited to, dichloromethane. Tautomers [00410] Compounds of the Formula I and sub-formulae thereof may exist in a number of different tautomeric forms and references to compounds of the Formula I and sub-formulae thereof include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by Formula I and sub-formulae thereof. Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), pyrimidone/hydroxypyrimidine, imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro. Isomers [00411] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”. [00412] Certain compounds of Formula I and sub-formulae thereof may have one or more asymmetric centres and therefore can exist in a number of stereoisomeric configurations. Consequently, such compounds can be synthesized and/or isolated as mixtures of enantiomers and/or as individual (pure) enantiomers, and, in the case of two or more asymmetric centres, single diastereomers and/or mixtures of diastereomers. It should be understood that the present application includes all such enantiomers and diastereomers and mixtures thereof in all ratios. Isotopes [00413] The compounds of the present invention are described herein using structural formulas that do not specifically recite the mass numbers or the isotope ratios of the constituent atoms. As such it is intended that the present application includes compounds in which the constituent atoms are present in any ratio of isotope forms. For example, carbon atoms may be present in any ratio of ¹² C, ¹³ C, and ¹⁴ C; hydrogen atoms may be present in any ratio of ¹ H, ² H, and ³ H; etc. Preferably, the constituent atoms in the compounds of the present invention are present in their naturally occurring ratios of isotope forms. Prodrugs and Metabolites [00414] The compounds of Formula I and sub-formulae thereof may be administered in the form of a pro-drug which is broken down in the human or animal body to release a compound of the invention. A pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property- modifying group can be attached. Examples of pro-drugs include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the Formula I and in-vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the Formula I and sub-formulae thereof. [00415] Accordingly, the present invention includes those compounds of the Formula I and sub-formulae thereof as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the Formula I that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the Formula I and sub-formulae thereof may be a synthetically-produced compound or a metabolically-produced compound. [00416] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I and sub-formulae thereof is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity. [00417] Various forms of pro-drug have been described, for example in the following documents :- a) Methods in Enzymology, Vol.42, p.309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p.113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987. [00418] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I and sub-formulae thereof that possesses a carboxy group is, for example, an in vivo cleavable ester thereof. An in vivo cleavable ester of a compound of the Formula I containing a carboxy group is, for example, a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically acceptable esters for carboxy include C _1-6 alkyl esters such as, but not limited to, methyl, ethyl and tert- butyl, C _1-6 alkoxymethyl esters such as, but not limited to, methoxymethyl esters, C _{1- 6} alkanoyloxymethyl esters such as, but not limited to, pivaloyloxymethyl esters, 3-phthalidyl esters, C _3-8 cycloalkylcarbonyloxy- C _1-6 alkyl esters such as, but not limited to, cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters, 2-oxo-1,3- dioxolenylmethyl esters such as, but not limited to, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and C _1-6 alkoxycarbonyloxy- C _1-6 alkyl esters such as, but not limited to, methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl esters. [00419] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I and sub-formulae thereof that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof. An in vivo cleavable ester or ether of a compound of the Formula I and sub-formulae thereof containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as, but not limited to, phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically acceptable ester forming groups for a hydroxy group include C _1-10 alkanoyl groups such as, but not limited to, acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C _{1- 10} alkoxycarbonyl groups such as, but not limited to, ethoxycarbonyl, N,N –(C _1-6 ) ₂ carbamoyl, 2- dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N- dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-( C _1-4 alkyl)piperazin-1- ylmethyl. Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include α-acyloxyalkyl groups such as, but not limited to, acetoxymethyl and pivaloyloxymethyl groups. [00420] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I and sub-formulae thereof that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as, but not limited to, ammonia, a C _1-4 alkylamine such as, but not limited to, methylamine, a (C _1-4 alkyl) ₂ amine such as, but not limited to, dimethylamine, N-ethyl-N-methylamine or diethylamine, a C _{1- 4} alkoxy- C _2-4 alkylamine such as, but not limited to, 2-methoxyethylamine, a phenyl- C _{1- 4} alkylamine such as, but not limited to, benzylamine and amino acids such as, but not limited to, glycine or an ester thereof. [00421] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I and sub-formulae thereof that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C _1-10 alkanoyl groups such as, but not limited to, an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N- alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4- (C _1-4 alkyl)piperazin-1-ylmethyl. [00422] The in vivo effects of a compound of the Formula I and sub-formulae thereof may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula I and sub-formulae thereof. As stated hereinbefore, the in vivo effects of a compound of the Formula I and sub-formulae thereof may also be exerted by way of metabolism of a precursor compound (a pro-drug). Pharmaceutical Compositions [00423] According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier. [00424] The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing). [00425] The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents. [00426] An effective amount of a compound of the present invention for use in therapy is an amount sufficient to treat or prevent a proliferative condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition. [00427] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 1.5 g of active agent (more suitably from 0.5 to 600 mg, for example from 1 to 200 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. [00428] The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine. [00429] It is to be noted that dosages and dosing regimens may vary with the type and severity of the condition to be alleviated, and may include the administration of single or multiple doses, i.e. QD (once daily), BID (twice daily), etc., over a particular period of time (days or hours). It is to be further understood that for any particular subject or patient, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the pharmaceutical compositions. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical effects such as toxic effects and/or laboratory values. Thus, the present application encompasses intra- patient dose-escalation as determined by the person skilled in the art. Procedures and processes for determining the appropriate dosage(s) and dosing regimen(s) are well-known in the relevant art and would readily be ascertained by the skilled artisan. As such, one of ordinary skill would readily appreciate and recognize that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the pharmaceutical compositions described herein. [00430] In using a compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous or intraperitoneal administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. [00431] For the compounds of the present invention, oral administration is particularly suitable. The compounds of the present invention may be formulated as a tablet, capsule or solution for oral administration. Suitably, the compound of the present invention is formulated in a unit dosage form (e.g. a tablet or capsule) for oral administration. Typically, unit dosage forms will contain about 0.5 mg to 1.5 g of a compound of this invention. Synthesis [00432] The compounds of the present invention can be prepared by any suitable technique known in the art. Particular methods for forming compounds of formula I defined herein are shown below and in the accompanying examples. [00433] In the description of the synthetic methods described herein and in any referenced synthetic methods that are used to prepare the starting materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be selected by a person skilled in the art. [00434] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions utilised. [00435] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed. [00436] For Examples of protecting groups see one of the many general texts on the subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule. [00437] Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. [00438] By way of example, a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as, but not limited to, acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or tbutoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as, but not limited to, an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tertbutoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. [00439] A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia. Alternatively, an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon. [00440] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon. [00441] Resins may also be used as a protecting group. [00442] The methodology employed to synthesise a compound of formula (I) will vary depending on the nature of R _N , R ₁ , V ₁ , and Q and any substituent groups associated therewith. Suitable processes for their preparation are described further in the accompanying Examples. [00443] Once a compound of formula (I) has been synthesised by any one of the processes defined herein, the processes may then further comprise one or more of the additional steps of: (i) removing any residual protecting groups present; (ii) converting the compound formula (I) into another compound of formula (I); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate of the compound of formula I; and/or (iv) forming a prodrug of the compound of formula I. [00444] An Example of (ii) above is when a compound of formula (I) is synthesised and then one or more of the groups of R _N , R ₁ , V ₁ , and Q may be further reacted to change the nature of the group and provide an alternative compound of formula (I). [00445] The resultant compounds of formula (I) can be isolated and purified using techniques well known in the art. Therapeutic Uses and Applications [00446] The compounds of the present invention are inhibitors of EGFR, including mutated forms of EGFR that are resistant to third generations EGFR inhibitors, such as osimertinib and lazertinib. Data showing the EGFR inhibitory activity of the exemplified compounds is presented in the accompanying example section. [00447] Accordingly, the compounds of formula I are useful for the treatment and/or prevention of diseases and conditions in which EGFR activity, including mutated forms of EGFR, is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer). [00448] Therefore, in one aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy. [00449] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition in which EGFR activity is implicated. [00450] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition associated with aberrant activity of EGFR. [00451] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of proliferative disorders (e.g. cancer). [00452] In another aspect, the present invention provides a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer. [00453] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a disease or condition in which EGFR activity is implicated. [00454] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a disease or condition associated with aberrant activity of EGFR. [00455] In another aspect, the present invention provides the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of proliferative disorders (e.g. cancer or benign neoplasms). [00456] In another aspect, the present invention the use of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer. [00457] In another aspect, the present invention provides a method of treating a disease or condition in which EGFR activity is implicated, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00458] In another aspect, the present invention provides a method of treating a disease or condition associated with aberrant activity of EGFR, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00459] In another aspect, the present invention provides a method of treating a proliferative disorder (e.g. cancer or benign neoplasms), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00460] In another aspect, the present invention provides a method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00461] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. [00462] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of EGFR positive non-small cell lung cancer. [00463] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [00464] In another aspect, the present invention provides a compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of non-small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [00465] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib. [00466] In another aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of non-small cell lung cancer resistant to treatment with osimertinib. [00467] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. [00468] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of EGFR positive non-small cell lung cancer. [00469] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [00470] In another aspect, the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of non-small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation). [00471] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib. [00472] In another aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for use in the treatment of non-small cell lung cancer resistant to treatment with osimertinib. [00473] In another aspect, the present invention provides a method of treating an EGFR positive cancer, optionally selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00474] In another aspect, the present invention provides a method of treating EGFR positive non-small cell lung cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00475] In another aspect, the present invention provides a method of treating a cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00476] In another aspect, the present invention provides a method of treating non- small cell lung cancer expressing a mutated form of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation), said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00477] In another aspect, the present invention provides a method of treating a cancer resistant to treatment with a third generation EFGR inhibitor, e.g. osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib and/or rociletinib, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00478] In another aspect, the present invention provides a method of treating non- small cell lung cancer resistant to treatment with osimertinib, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein. [00479] The terms "proliferative disorder" and “proliferative condition” are used interchangeably herein and pertain to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo. [00480] Examples of proliferative conditions include, but are not limited to, pre- malignant and malignant cellular proliferation, including but not limited to, cancers, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Any type of cell may be treated. [00481] Cancers associated with aberrant EGFR activity (including its mutated forms - for example EGFR comprising a T790M mutation, a deletion in exon 19 (such as A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation) are of particular interest. Thus, the compounds of the present invention may be used to treat any EGFR positive cancer. Particular examples of such cancers include head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. A particular cancer of interest is non-small cell lung cancer. [00482] Thus, in certain aspects of the present invention, the proliferative disorder is cancer, suitably a cancer selected from head and neck cancer, brain cancer, breast cancer, colon cancer and/or lung cancer. [00483] In a particular aspect of the invention, the proliferative disorder is non-small cell lung cancer. [00484] It will be appreciated that the compounds of the present invention could be used to treat any EGFR positive cancer. The invention therefore encompasses the treatment of any EGFR positive non-metastatic or metastatic cancer and which may be a solid tumour or a haematological (“liquid”) cancer. The cancer may, for example, be selected from: (1) Carcinoma, including for example tumours derived from stratified squamous epithelia (squamous cell carcinomas) and tumours arising within organs or glands (adenocarcinomas). Examples include breast, colon, lung, prostate, ovary, esophageal carcinoma (including, but not limited to, esophageal adenocarcinoma and squamous cell carcinoma), basal-like breast carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (various tissues), head and neck carcinoma (including, but not limited to, squamous cell carcinomas), stomach carcinoma (including, but not limited to, stomach adenocarcinoma, gastrointestinal stromal tumor), signet ring cell carcinoma, bladder carcinoma (including transitional cell carcinoma (a malignant neoplasm of the bladder)), bronchogenic carcinoma, colorectal carcinoma (including, but not limited to, colon carcinoma and rectal carcinoma), anal carcinoma, gastric carcinoma, lung carcinoma (including but not limited to small cell carcinoma (SCLC) and non-small cell carcinoma of the lung (NSCLC), lung adenocarcinoma, squamous cell carcinoma, large cell carcinoma, bronchioloalveolar carcinoma, and mesothelioma), neuroendocrine tumors (including but not limited to carcinoids of the gastrointestinal tract, breast, and other organs), adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma (including, but not limited to, pancreatic ductal adenocarcinoma, pancreatic adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with invasive carcinoma, mucinous cystic neoplasm with invasive carcinoma, islet cell carcinoma and neuroendocrine tumors), breast carcinoma (including, but not limited to, ductal carcinoma, lobular carcinoma, inflammatory breast cancer, clear cell carcinoma, mucinous carcinoma), ovarian carcinoma (including, but not limited to, ovarian epithelial carcinoma or surface epithelial-stromal tumor including serous tumor, endometrioid tumor and mucinous cystadenocarcinoma, sex-cord- stromal tumor), liver and bile duct carcinoma (including, but not limited to, hepatocellular carcinoma, cholangiocarcinoma and hemangioma), prostate carcinoma, adenocarcinoma, brain tumours (including, but not limited to glioma, glioblastoma and medulloblastoma), germ cell tumors, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, kidney carcinoma (including, but not limited to, renal cell carcinoma, clear cell carcinoma and Wilm's tumor), medullary carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, cervical carcinoma, uterine carcinoma (including, but not limited to, endometrial adenocarcinoma, uterine papillary serous carcinoma, uterine clear-cell carcinoma, uterine sarcomas and leiomyosarcomas, mixed mullerian tumors), testicular carcinoma, osteogenic carcinoma, epithelial carcinoma, sarcomatoid carcinoma, nasopharyngeal carcinoma, laryngeal carcinoma; oral and oropharyngeal squamous carcinoma; (2) Sarcomas, including: osteosarcoma and osteogenic sarcoma (bone); chondrosarcoma (cartilage); leiomyosarcoma (smooth muscle); rhabdomyosarcoma (skeletal muscle); mesothelial sarcoma and mesothelioma (membranous lining of body cavities); fibrosarcoma (fibrous tissue); angiosarcoma and hemangioendothelioma (blood vessels); liposarcoma (adipose tissue); glioma and astrocytoma (neurogenic connective tissue found in the brain); myxosarcoma (primitive embryonic connective tissue); chordoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, Ewing's sarcoma, mesenchymous and mixed mesodermal tumor (mixed connective tissue types) and other soft tissue sarcomas; (3) Myeloma and multiple myeloma; (4) Hematopoietic tumours, including: myelogenous and granulocytic leukemia (malignancy of the myeloid and granulocytic white blood cell series); lymphatic, lymphocytic, and lymphoblastic leukemia (malignancy of the lymphoid and lymphocytic blood cell series); polycythemia vera and erythremia (malignancy of various blood cell products, but with red cells predominating); myelofibrosis. (5) Lymphomas, including: Hodgkin and Non-Hodgkin lymphomas; (6) Solid tumors of the nervous system including medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma and schwannoma; (7) Melanoma, uveal melanoma and retinoblastoma; and (8) Mixed Types, including, e.g., adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma or teratocarcinoma. Routes of Administration [00485] The compounds of the invention or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or topically (i.e., at the site of desired action). [00486] Routes of administration include, but are not limited to, oral (e.g. by ingestion); buccal; sublingual; transdermal (e.g. by a patch, plaster, etc.); transmucosal (e.g. by a patch, plaster, etc.); intranasal (e.g. by nasal spray); ocular (e.g. by eye drops, eye ointment etc.); pulmonary (e.g. by inhalation or insufflation therapy, for example via an aerosol, for example by the nose or mouth); rectal (e.g. by suppository or enema); vaginal (e.g. by pessary); parental, for example by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir dosage form, for example subcutaneously or intramuscularly. [00487] The compounds of the present invention are particularly suitable for oral administration. Combination Therapies [00488] The compounds of the invention and salts, solvates thereof defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, one or more additional therapeutic agents, e.g. an anti-tumour agent. [00489] In the context of cancer treatment, in addition to the compound of the invention therapy may involve conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:- - other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as, but not limited to, alkylating agents (for example cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as, but not limited to, fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin); - cytostatic agents such as, but not limited to, antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α-reductase such as, but not limited to, finasteride; - anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3- methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]- 5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Application WO 01/94341), N-(2-chloro-6- methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-meth ylpyrimidin-4-ylamino}thiazole- 5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658-6661) and bosutinib (SKI-606), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase]; - inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. (Critical reviews in oncology/haematology, 2005, Vol. 54, pp11-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example other EGFR family tyrosine kinase inhibitors such as, but not limited to, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy )quinazolin-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-ami ne (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinoprop oxy)- quinazolin-4-amine (CI 1033), afatinib, . osimertinib, lazertinib (YH25448), EGF816, olmutinib, PF-06747775, avitinib, rociletinib; erbB2 tyrosine kinase inhibitors such as, but not limited to, lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family such as, but not limited to, imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as, but not limited to, farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin dependent kinase inhibitors such as, but not limited to, CDK2 and/or CDK4 inhibitors; - antiangiogenic agents such as, but not limited to, those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and for example, a VEGF receptor tyrosine kinase inhibitor such as, but not limited to, vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4-fluoro-2-methylindol-5-yloxy)-6- methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), compounds such as, but not limited to, those disclosed in International Patent Applications WO97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin αvβ3 function and angiostatin)]; - vascular damaging agents such as, but not limited to, Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; - an endothelin receptor antagonist, for example zibotentan (ZD4054) or atrasentan; - antisense therapies, for example those which are directed to the targets listed above, such as, but not limited to, ISIS 2503, an anti-ras antisense; - gene therapy approaches, including for example approaches to replace aberrant genes such as, but not limited to, aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as, but not limited to, those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and - immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as, but not limited to, transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as, but not limited to, cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies. [00490] In a particular embodiment, the antiproliferative treatment defined hereinbefore may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. [00491] In a further particular embodiment, the antiproliferative treatment defined hereinbefore may involve, in addition to the compound of the invention, standard chemotherapy for the cancer concerned. [00492] Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range. [00493] According to this aspect of the invention there is provided a combination for use in the treatment of a cancer (for example a cancer involving a solid tumour) comprising a compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and another anti-tumour agent, or a pharmaceutically acceptable salt thereof. [00494] According to this aspect of the invention there is provided a combination for use in the treatment of a proliferative condition, such as, but not limited to, cancer (for example a cancer involving a solid tumour), comprising a compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and any one of the anti-tumour agents listed herein above. [00495] In a further aspect of the invention there is provided a compound of the invention or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of cancer in combination with another anti-tumour agent, optionally selected from one listed herein above. [00496] Herein, where the term “combination” is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention “combination” refers to simultaneous administration. In another aspect of the invention “combination” refers to separate administration. In a further aspect of the invention “combination” refers to sequential administration. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination. In one embodiment, a combination refers to a combination product. [00497] According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with an anti-tumour agent (optionally selected from one listed herein above), in association with a pharmaceutically acceptable diluent or carrier. Biological Activity [00498] The biological assays described in the example section may be used to measure the pharmacological effects of the compounds of the present invention. Although the pharmacological properties of the compounds of formula I vary with structural change, as expected, the compounds of the invention were found to be active in the assays described in the example section below. EXAMPLES [00499] The invention will now be illustrated, but not limited, by reference to the specific embodiments described in the following examples. Compounds are named using conventional IUPAC nomenclature, or as named by the chemical supplier. [00500] The following synthetic procedures are provided for illustration of the methods used; for a given preparation or step the precursor used may not necessarily derive from the individual batch synthesized according to the step in the description given. General Information [00501] Chemicals were purchased from commercial suppliers and used without further purification. Thin layer chromatography (TLC) was performed on aluminium plates coated with 60 F254 silica from Merck. Flash chromatography was carried out using a Biotage SP4, Biotage Isolera, or Varian automated flash system with Silicycle or GraceResolve normal phase silica gel prepacked columns. Fractions were collected at 254 nm or if necessary, on all wavelengths between 200 and 400 nm. Microwave irradiation was performed in a Biotage Initiator Sixty in sealed vials. Reactions were irradiated at 2.45 GHz and were able to reach temperatures between 60 and 250 °C. Heating was at a rate of 2–5 °C/s, and the pressure was able to reach 20 bar. Final compound purity is >95%. Flash chromatography was also carried out using a Biotage SP4, Biotage Isolera Prime, Varian or Agela Technologies automated flash system with GraceResolve normal phase silica gel pre-packed columns, Welch Technology or Agela Technologies normal phase silica gel columns or reverse phase C18 columns. Fractions were collected at 254 nm or if necessary, on all wavelengths between 200 and 400 nm. Microwave irradiation was performed in a Biotage Initiator Sixty in sealed vials. Reactions were irradiated at 2.45 GHz and were able to reach temperatures between 40 and 300 °C. Heating was at a rate of 2-5 °C/s and the pressure was able to reach 20 bar. Analytical Equipment [00502] LC-MS analyses were conducted using a Waters Acquity UPLC system or Shimadzu LCMS-2020 with photo diode array (PDA) and evaporating light scattering detector (ELSD). When a 2 min gradient was used, the sample was eluted on an Acquity UPLC BEH C18, 1.7 µm (2.1 x 50mm) with a flow rate of 0.6mL/min using 5-95% 0.1% HCOOH in MeCN or LCMS Ascentis Express 90 A C182.7 µm (3cm x 3.0mm) with a flow rate of 1.2 mL/min using 5-95% 0.1% HCOOH in MeCN or Poroshell HPH-C18, 4.0 µm (5cm x 3.0mm) with a flow rate of 1.2 mL/min using 5-95% 5 mmol NH ₄ HCO ₃ in MeCN. The analytical purity of compounds was determined using Waters XTerra RP18, 5 µm (4.6 x 150 mm) column at 1 mL/min either using 0.1% aq. ammonia and MeCN or 0.1% aq. HCOOH and MeCN with a gradient of 5-100% over 15 min or Shimadzu Ascentis Express C18, 2.7 μm (4.6 × 100 mm) column or Agilent EVO C18, 2.6 μm (3.0 × 100 mm) column at 1 mL/min using either 0.05% aq. ammonia and MeCN or 0.1% aq. TFA and MeCN with a gradient of 5-100% over 15 min. [00503] ¹ H NMR spectra were obtained using a Bruker Avance III 500 spectrometer using a frequency of 500 MHz, a Bruker BioSpin AG Avanace III HD using a frequency of 300 MHz or a Bruker BioSpin AG Avanace NEO using a frequency of 400 MHz. ¹³ C spectra were acquired using the Bruker Avance III 500 spectrometer operating at a frequency of 126 MHz. The abbreviations for spin multiplicity are as follows: s = singlet; d = doublet; t = triplet; q = quartet; p = quintuplet; h = sextuplet; m = multiplet. Combinations of these abbreviations are employed to describe more complex splitting patterns (e.g., dd = doublet of doublets). General Procedures General procedure 1: [00504] To a stirred solution/mixture of ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5- carboxylate (1.0 eq.) in THF (300 mL) was added amine (1.5 eq.) dropwise at 0 °C under nitrogen. Once completed, the resulting mixture was filtered, the filter cake was washed with THF (2 x 50 mL). General procedure 2: [00505] A solution of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (1.0 eq.), triethylamine (2.5 eq.) and amine (1.0 eq.) in THF (0.4 M) was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate (250 mL) and water (250 mL). The organic phase was separated and concentrated under reduced pressure. General procedure 3: [00506] A solution of ester (1.0 eq.) and sodium hydroxide (5 eq.) in THF (250 mL) and water (250 mL) was stirred at 50 °C overnight. The resulting mixture was concentrated under reduced pressure to remove most of THF. Then the pH value was adjusted to 3-4 with 4 M aqueous hydrochloric acid and either the precipitate was collected by filtration, washing with water or the aqueous solution was extracted with ethyl acetate (3 x 250 mL). The combined organic extracts were concentrated under reduced pressure. General procedure 4: [00507] To a stirred solution of carboxylic acid (1.0 eq.) and 1H-benzo[d][1,2,3]triazole (1.0 eq.) in dichloromethane (0.3 M) was added EDCI (1.0 eq.). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was quenched with water (100 mL), the organic phase was separated and concentrated to dryness under reduced pressure. General procedure 5: [00508] To a solution of ethyl acetate (2.7 eq.) in THF (0.2 M) was slowly added LiHMDS (1M in THF, 2.7 eq.) at -78 °C. The mixture was stirred for another 30 min at -78 °C, then a solution of dicarbonyl (1.0 eq.) in THF (0.2 M) was added to the solution at -78 °C. The resulting mixture was warmed to room temperature and stirred overnight. The reaction was quenched by 1 M aqueous hydrochloric acid then the pH was adjusted to 2 with 6 M aqueous hydrochloric acid and extracted with dichloromethane. The organic layers were combined, dried (Na ₂ SO ₄ ) and concentrated under reduced pressure. General procedure 6: [00509] A solution of oxopropanoate (1.0 eq.), N,N-diisopropylethylamine (10 eq.) and DBU (2.0 eq.) was stirred at 120 °C for 1 hour then cooled. The solvent was decanted and the residual thick brown oil was dissolved in water (20 mL). The aqueous solution was acidified to pH 2 with 4 M aqueous hydrochloric acid. The resulting solids were collected by vacuum filtration, washing with water and 40-60 petroleum ether then dried under vacuum. General procedure 7: [00510] To a stirred solution of pyrimidine (1.0 eq.) in DMF (0.25 M) at 0 °C was slowly added sodium hydride (5.0 eq.). After 15 minutes at room temperature, the solution was cooled to 0 °C and the acyl chloride (1.2 eq.) was slowly added. After 1 hour at room temperature, the reaction was quenched with ice-water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The aqueous layer was acidified to pH 5 with 5% aqueous hydrochloric acid and the resulting precipitate was collected by vacuum filtration or the combined organic layers were dried (Na ₂ SO ₄ ) and concentrated under reduced pressure. General procedure 8: [00511] To a stirred solution/mixture of pyrido[2,3-d]pyrimidine-5,7-dione (1.0 eq.) and triethylamine (2.0 eq.) in dichloromethane (0.5 M) was added triflic anhydride (1.5 eq.) dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure. General procedure 9: [00512] A solution of triflate (1.0 eq.), bis(triphenylphosphine)palladium chloride (0.10 eq.), triisopropylsilylacetylene (2.0 eq.), copper(I) iodide (0.10 eq.), N,N-diisopropylethylamine (3.0 eq.) in DMF (0.2 M). The resulting mixture was stirred for 3 h at 80 °C under a nitrogen atmosphere. The resulting mixture was filtered, the filter cake was washed with dichloromethane (2 x 10 mL). General procedure 10: [00513] Methylthiol (1.0 eq.) and mCPBA (3.0 eq.) in dichloromethane (0.1 M) were stirred at room temperature for 1-2 hours. The reaction mixture was quenched with saturated aqueous sodium thiosulphate solution (20 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were washed with saturated aqueous sodium thiosulfate solution (3 x 20 mL) and saturated aqueous sodium hydrogen carbonate solution (3 x 30 mL). The organic layer was dried (MgSO ₄ ) and concentrated under reduced pressure. The crude material was carried into the subsequent step without further purification. General procedure 11: [00514] p-fluoronitrophenyl (1.0 eq.), amine (1.0-2.0 eq.) and potassium carbonate (1.5-2.0 eq.) in DMSO (0.6-1.0 M) was stirred at room temperature overnight. The reaction mixture was poured onto water (30 mL) and the resulting precipitate collected by vacuum filtration washing with water and dried in a vacuum over overnight, or extracted with dichloromethane (3 x 50 mL), the combined organic extracts dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 12: [00515] To a solution of nitro (1.0 eq.) in ethanol, methanol (0.25 M) or ethanol:acetic acid (1:1, 0.25 M) was added palladium on carbon 5-10 wt. % (0.1 eq.). The reaction mixture was stirred at room temperature overnight under an atmosphere of hydrogen. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. General procedure 13: [00516] Methylsulfonyl (1.0 eq.), aniline (1.0-1.5 eq.) and trifluoroacetic acid (1.0-1.5 eq.) in acetonitrile or n-butanol (0.1 M) were stirred at 80-110 °C overnight or for the specified time. The reaction mixture was concentrated under reduced pressure. General procedure 14: [00517] Methylsulfonyl (1.0 eq.), amine (1.5 eq.) and N,N-diisopropylethylamine (5.0 eq.) in DMSO (0.25 M) were stirred at 60 °C overnight. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (30 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 15: [00518] TIPS-protected alkyne (1.0 eq.) and potassium fluoride (1.0-20 eq.) in solvent (0.1 M) was stirred at the specified temperature until completion. The solvent was removed under reduced pressure. General procedure 16: [00519] TES-protected alkyne (1.0 eq.) and potassium carbonate (1.0 eq.) in methanol (0.1 M) was stirred at 40 °C overnight. The solvent was removed under reduced pressure. The residue was suspended in water and the resulting precipitate collected by vacuum filtration, washing with water. General procedure 17: [00520] To a solution of bromide (1.0 eq.) and boronic acid (1.5 eq.) in dioxane (0.2 M) and water (0.45 M) was added potassium carbonate (2.0 eq.) and 1,1'- Bis(diphenylphosphino)ferrocene)palladium(II) dichloride (0.1 eq.). The reaction was stirred for 3 h at 70 °C under a nitrogen atmosphere, then concentrated under reduced pressure. General procedure 18: [00521] Pyridone (1.0 eq.), alcohol (1.1 eq.), triphenylphosphine (1.5-2.0 eq.) and DEAD or DIAD (1.5-2.0 eq.) in solvent (0.5 M) were stirred at room temperature for 1 h. The reaction mixture was quenched with water (30 mL), extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 19 [00522] To a stirred solution of triflate (1.0 eq.) and bis(triphenylphosphine)palladium (II) dichloride (0.05 eq.) in toluene (0.14 M) was added vinyl tributyltin (1.4 eq.). The reaction was stirred at 80 °C for 1-2 h, then concentrated under reduced pressure. The residue was dissolved in hexane and extracted with acetonitrile. The acetonitrile layer was separated and concentrated under reduced pressure. General procedure 20 [00523] Hydroxyl (1.0 eq.), triphenylphosphine (4.0 eq.) and DIAD (4.0 eq.) in THF (0.024 M) were stirred at room temperature for 1-2h. The reaction mixture was quenched with water (30 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 21 [00524] To a stirred solution of alcohol (1.0 eq.) and silyl chloride (1.0-1.1 eq.) in THF (0.5 M) was added sodium hydride (1.0-1.1 eq.). The reaction was stirred at room temperature overnight, then quenched with saturated aqueous ammonium chloride solution (30 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 22 [00525] Phenol (1.0 eq.), hydroxyl (1.1 eq.), triphenylphosphine (1.3 eq.) and DIAD (1.3 eq.) in THF (0.2 M) were stirred at room temperature overnight. The reaction mixture was quenched with water (30 mL), extracted with dichloromethane (3 x 30 mL). The combined organic extracted with dried (MgSO ₄ ) and concentrated under reduced pressure. General procedure 23 [00526] To a stirred solution of nitro (1.0 eq.) in methanol (0.4 M) was added iron (5.0 eq.) and saturated aqueous ammonium chloride solution (0.8 M). The reaction mixture was stirred at 60 °C for 2-4 h. The reaction mixture was filtered through celite, washing with dichloromethane and methanol. The filtrate was separated, with the aqueous layer extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried (MgSO ₄ ) and concentrated under reduced pressure. Example 1 Ethyl 2-(methylsulfanyl)-4-(phenylamino)pyrimidine-5-carboxylate [00527] General procedure 2 was applied to ethyl 4-chloro-2- (methylsulfanyl)pyrimidine-5-carboxylate (100 g, 425 mmol), THF (1.0 L), triethylamine (129 g, 1.28 mol) and aniline (59.4 g, 638 mmol). The residue was slurried in 40-60 petroleum ether (100 mL) and filtered. The filter cake was washed with 40-60 petroleum ether and then dried under vacuum to yield the title compound as an off-white solid (115 g, 93%), which was used in next step without any further purification. [00528] (ES, m/z): [M+H] ⁺ = 289.9 2-(Methylsulfanyl)-4-(phenylamino)pyrimidine-5-carboxylic acid [00529] General procedure 3 was applied to ethyl 2-(methylsulfanyl)-4- (phenylamino)pyrimidine-5-carboxylate (147 g, 507 mmol) and sodium hydroxide (71.0 g, 1.78 mol) in THF (1.5 L) and water (1.5 L) to afford the title compound as a white solid (110 g, 82%). [00530] (ES, m/z): [M+H] ⁺ = 261.9 5-(1,2,3-Benzotriazole-1-carbonyl)-2-(methylsulfanyl)-N-phen ylpyrimidin-4-amine [00531] General procedure 4 was applied to 2-(methylsulfanyl)-4- (phenylamino)pyrimidine-5-carboxylic acid (30.0 g) with EDCI (22.1 g) and benzotriazole (13.7 g) in dichloromethane (300 mL). The residue was purified by flash column chromatography eluting with ethyl acetate (10%) in 40-60 petroleum ether to yield the title compound as a yellow solid (35.6 g, 85% yield). [00532] (ES, m/z): [M+H] ⁺ = 363 Ethyl 3-(2-(methylthio)-4-(phenylamino)pyrimidin-5-yl)-3-oxopropan oate [00533] General procedure 5 was applied to (1H-benzo[d][1,2,3]triazol-1-yl)(2- (methylthio)-4-(phenylamino)pyrimidin-5-yl)methanone (22.7 g, 62.7 mmol) with ethyl acetate (13.8 g, 157 mmol) and LiHMDS (1M, 157 mL, 157 mmol) in THF (550 mL) to yield the title compound as a light yellow solid (12.6 g, 61%). [00534] (ES, m/z): [M+H] ⁺ = 332 5-Hydroxy-2-(methylthio)-8-phenylpyrido[2,3-d]pyrimidin-7(8H )-one [00535] General procedure 6 was applied to ethyl 3-(2-(methylthio)-4- (phenylamino)pyrimidin-5-yl)-3-oxopropanoate (12.6 g, 38.1 mmol) with N,N- diisopropylethylamine (51.0 mL, 29.2 mmol) and DBU (6.50 mL, 43.5 mmol) to yield the title compound as a as light brown solid (10.5 g, 97%). [00536] (ES, m/z): [M+H] ⁺ = 286. 2-(Methylthio)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimi din-5-yl trifluoromethanesulfonate [00537] General procedure 8 was applied to 5-hydroxy-2-(methylthio)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one (10.9 g, 38.3 mmol) with trifluoromethanesulfonic anhydride (16.2 g, 57.5 mmol) and triethylamine (5.82 g, 57.5 mmol) in dichloromethane (220 mL). The crude material was purified by flash column chromatography eluting with ethyl acetate (0-50%) in 40-60 petroleum ether to yield the title compound as a light yellow solid (8.80 g, 55%). [00538] (ES, m/z): [M+H] ⁺ = 418. 2-(Methylthio)-8-phenyl-5-((triisopropylsilyl)ethynyl)pyrido [2,3-d]pyrimidin-7(8H)-one [00539] General procedure 9 was applied to 2-(methylthio)-7-oxo-8-phenyl-7,8- dihydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (2.00 g, 4.80 mmol) with triisopropylsilyl acetylene (1.75 g, 9.60 mmol), copper(I) iodide (92.0 mg, 0.480 mmol), bis(triphenylphosphine)palladium(II) dichloride (338 mg, 0.480 mmol) in DMF (20 mL) and N,N-diisopropylethylamine (10 mL). The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a light yellow solid (1.71 g, 80%). [00540] (ES, m/z): [M+H] ⁺ = 450. 2-(Methylsulfonyl)-8-phenyl-5-((triisopropylsilyl)ethynyl)py rido[2,3-d]pyrimidin-7(8H)- one [00541] General procedure 10 was applied to 2-(methylthio)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-one (1.70 g, 3.78 mmol) with m-CPBA (1.96 g, 11.4 mmol) in dichloromethane (90 mL). The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (1.62 g, 89%). [00542] (ES, m/z): [M+H] ⁺ = 482. 2-((2-Methoxyphenyl)amino)-8-phenyl-5-((triisopropylsilyl)et hynyl)pyrido[2,3- d]pyrimidin-7(8H)-one [00543] General procedure 13 was applied to 2-(methylsulfonyl)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-one (1.32 g, 2.74 mmol) with 2- methoxyaniline (338 mg, 2.74 mmol) and trifluoroacetic acid (313 mg, 2.74 mmol) in 2-butanol (10 mL). The reaction mixture was stirred at 110 °C for 16 h. The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (1.06 g, 74%). [00544] (ES, m/z): [M+H] ⁺ = 525. 5-Ethynyl-2-[(2-methoxyphenyl)amino]-8-phenylpyrido[2,3-d]py rimidin-7-one [00545] General procedure 15 was applied to 2-[(2-methoxyphenyl)amino]-8-phenyl-5- [2-(triisopropylsilyl)ethynyl]pyrido[2,3-d]pyrimidin-7-one (823 mg, 1.56 mmol), potassium fluoride (9.12 g, 156 mmol) in THF and water (22.0 mL, 10:1). The resulting solution was stirred for 48 h at 40 °C. The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (520 mg, 90%). [00546] (ES, m/z): [M+H] ⁺ = 369. [00547] ¹ H NMR (300 MHz, CDCl ₃ ) δ 8.91 (s, 1H), 8.10 (s, 1H), 7.76 – 7.49 (m, 4H), 7.36 – 7.30 (m, 2H), 6.98 – 6.86 (m, 1H), 6.86 – 6.73 (m, 2H), 6.52 (s, 1H), 3.88 (s, 3H), 3.71 (s, 1H). Example 2 5-(Bis(4-methoxybenzyl)amino)-2-(methylthio)-8-phenylpyrido[ 2,3-d]pyrimidin-7(8H)- one [00548] A solution of 2-(methylthio)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimi din- 5-yl trifluoromethanesulfonate (1.00 g, 2.40 mmol, 1.0 eq.), bis(4-methoxybenzyl)amine (1.85 g, 7.20 mmol, 3.0 eq.) in DCE (15 mL) was heated to 100 °C under microwave irradiation for 6 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a white solid (1.80 g, 72%). [00549] (ES, m/z): [M+H] ⁺ = 525. 5-Amino-2-(methylthio)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)- one [00550] A solution of 5-(bis(4-methoxybenzyl)amino)-2-(methylthio)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one (1.80 g, 3.44 mmol, 1.0 eq.) in trifluoroacetic acid (20 mL) was stirred at 60 °C for 1 h. The reaction mixture was concentrated under reduced pressure and the residue dissolved in DMSO (5 mL). The DMSO solution was adjusted to neutral pH with triethylamine and purified by reverse phase flash column chromatography eluting with acetonitrile (15-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a white solid (700 mg, 71%). [00551] (ES, m/z): [M+H] ⁺ = 285. tert-Butyl (2-(methylthio)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrim idin-5- yl)carbamate [00552] To a stirred solution of 5-amino-2-(methylthio)-8-phenylpyrido[2,3-d]pyrimidin- 7(8H)-one (700 mg, 2.46 mmol, 1.0 eq.), Boc anhydride (808 mg, 3.70 mmol, 1.5 eq.) and DMAP (30.0 mg, 0.246 mmol, 0.1 eq.) in dichloromethane (10 mL) at 0 °C was added triethylamine (497 mg, 4.92 mmol, 2.0 eq.) dropwise. The reaction was stirred at room temperature for 1 h before being diluted with water (25 mL) and dichloromethane (20 mL). The organic layer was separated, dried (Na ₂ SO ₄ ) and concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate (0-50%) in 40- 60 petroleum ether to yield a mixture of the title compound and the doubly protected product as a yellow solid (1.00 g, 100%). [00553] (ES, m/z): [M+H] ⁺ = 385. tert-Butyl (2-(methylsulfonyl)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]p yrimidin-5- yl)carbamate [00554] General procedure 10 was applied to tert-butyl (2-(methylthio)-7-oxo-8-phenyl- 7,8-dihydropyrido[2,3-d]pyrimidin-5-yl)carbamate (1.00 g, 2.46 mmol) and m-CPBA (1.50 g, 7.38 mmol) in dichloromethane (30 mL). The residue was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (800 mg, 78%). [00555] (ES, m/z): [M+H] ⁺ = 417. Tert-Butyl (2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyrido [2,3- d]pyrimidin-5-yl)carbamate [00556] General procedure 13 was applied to tert-butyl (2-(methylsulfonyl)-7-oxo-8- phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-5-yl)carbamate (800 mg, 1.92 mmol), 2- methoxyaniline (236 mg, 1.92 mmol) and trifluoroacetic acid (186 mg, 1.92 mmol) and 2- butanol (10 mL). The reaction mixture was stirred at 110 °C for 16 h. The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (25-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (500 mg, 57%). [00557] (ES, m/z): [M+H] ⁺ = 460. 5-Amino-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]pyri midin-7(8H)-one [00558] A solution of tert-butyl (2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8- dihydropyrido[2,3-d]pyrimidin-5-yl)carbamate (500 mg, 1.09 mmol, 1.0 eq.) and trifluoroacetic acid (5.0 mL) in dichloromethane (10 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to yield the title compound which was used without purification. N-(2-((2-Methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyri do[2,3-d]pyrimidin-5- yl)acrylamide [00559] To a stirred solution of 5-amino-2-((2-methoxyphenyl)amino)-8- phenylpyrido[2,3-d]pyrimidin-7(8H)-one (90.0 mg, 0.250 mmol, 1.0 eq.), DMAP (3.00 mg, 25.0 μmol, 0.1 eq.), triethylamine (50.0 mg, 0.500 mmol, 2.0 eq.) and dichloromethane (5 mL) at 0 °C was added acryloyl chloride (23.0 mg, 0.250 mmol, 1.0 eq.) dropwise. The reaction was stirred at room temperature for 1 h before being diluted with water (25 mL) and dichloromethane (20 mL). The dichloromethane layer was separated, dried (Na ₂ SO ₄ ) and concentrated under reduced pressure. The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (20-100%) in water (0.1% formic acid) to yield the title compound as a yellow solid (10.0 mg, 10%). [00560] (ES, m/z): [M+H] ⁺ = 414. [00561] ¹ H NMR (400 MHz, CDCl ₃ ) δ 10.74 (s, 1H), 9.21 (s, 1H), 8.24 (s, 4H), 7.59 – 7.54 (m, 3H), 7.37 – 7.31 (m, 3H), 6.96 – 6.89 (m, 2H), 6.43 - 6.45 (m, 1H), 3.81 (s, 3H), 2.82 – 2.79 (m, 2H), 2.68 – 2.60 (m, 2H). Example 3 6-(Methylsulfanyl)-4-(phenylamino)pyridine-3-carboxylic acid [00562] A solution of ethyl 6-chloro-4-(phenylamino)pyridine-3-carboxylate (12.0 g, 43.4 mmol, 1.0 eq.) and sodium thiomethoxide (6.00 g) in DMF (50 mL) was stirred for 5 h at room temperature. The resulting mixture was diluted with water (50 mL). The resulting mixture was concentrated under reduced pressure to yield the title compound as an off-white solid (8.00 g, 71%). 5-(1,2,3-Benzotriazole-1-carbonyl)-2-(methylsulfanyl)-N-phen ylpyridin-4-amine [00563] General procedure 4 was applied to 6-(methylsulfanyl)-4- (phenylamino)pyridine-3-carboxylic acid (12.0 g, 46.1 mmol), benzotriazole (6.00 g, 50.4 mmol) and EDCI (13.0 g, 67.8 mmol) in dichloromethane (100 mL). The residue was purified by flash column chromatography, eluting with ethyl acetate (10%) in 40-60 petroleum ether to afford the title compound as a white solid (3.00 g, 18 %). Ethyl 3-[6-(methylsulfanyl)-4-(phenylamino)pyridin-3-yl]-3-oxoprop anoate [00564] General procedure 5 was applied to 5-(1,2,3-benzotriazole-1-carbonyl)-2- (methylsulfanyl)-N-phenylpyridin-4-amine (3.30 g, 9.13 mmol), ethyl acetate (2.30 mL, 23.5 mmol) and 1M LiHMDS in hexane (23.1.0 mL, 23.5 mmol) in THF (50 & 10 mL).The crude product was purified by flash column chromatography eluting with ethyl acetate (10%) in 40- 60 petroleum ether to afford the title compound as an off-white solid (2.00 g, 66%). 4-Hydroxy-7-(methylsulfanyl)-1-phenyl-1,6-naphthyridin-2-one [00565] General procedure 6 was applied to ethyl 3-[6-(methylsulfanyl)-4- (phenylamino)pyridin-3-yl]-3-oxopropanoate (2.00 g, 6.05 mmol) and DBU (0.50 mL, 3.35 mmol) in N,N-diisopropylethylamine (20 mL) to yield the title compound as an off-white solid (1.60 g, 93%). 7-(Methylsulfanyl)-2-oxo-1-phenyl-1,6-naphthyridin-4-yl trifluoromethanesulfonate [00566] General procedure 8 was applied to 4-hydroxy-7-(methylsulfanyl)-1-phenyl- 1,6-naphthyridin-2-one (1.60 g, 5.63 mmol), triethylamine (2.00 mL, 19.7 mmol) and triflic anhydride (2.00 g, 7.09 mmol) in dichloromethane. The precipitated solids were collected by filtration to yield the title compound as a brown solid (2.10 g, 90%). 7-(Methylsulfanyl)-1-phenyl-4-[2-(triisopropylsilyl)ethynyl] -1,6-naphthyridin-2-one [00567] General procedure 9 was applied to triisopropylsilylacetylene (276 mg, 1.51 mmol) and 7-(methylsulfanyl)-2-oxo-1-phenyl-1,6-naphthyridin-4-yl trifluoromethanesulfonate (312 mg, 0.749 mmol), palladium(II) chloride (40.0 mg, 0.23 mmol), copper(I) iodide (40.0 mg, 0.21 mmol) and triphenylphosphine (90.0 mg, 0.205 mmol) in DMF (3.00 mL) and N,N- diisopropylethylamine (1.5 mL). The residue was purified by preparative TLC eluting with ethyl acetate (10%) in 40-60 petroleum ether to afford the title compound as a pink solid (200 mg, 59%). 7-[(2-Methoxyphenyl)amino]-1-phenyl-4-[2-(triisopropylsilyl) ethynyl]-1,6-naphthyridin- 2-one [00568] To a solution of 7-(methylsulfanyl)-1-phenyl-4-[2-(triisopropylsilyl)ethynyl] -1,6- naphthyridin-2-one (200 mg, 0.446 mmol, 1.0 eq.) and o-anisidine (110 mg, 0.893 mmol, 2.0 eq.) in toluene (5.0 mL) was added LiHMDS (1.20 mL, 7.17 mmol, 16 eq.) and nickeldicarbaldehyde (20.0 mg, 0.168 mmol, 0.4 eq.) and 1,2- bis(dicyclohexylphosphino)ethane (20.0 mg, 0.047 mmol, 0.1 eq.). After stirring for 1 day at 100 °C under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash column chromatography eluting with acetonitrile (10-50%) in water to yield the title compound as a yellow solid (50.0 mg, 21%). 4-Ethynyl-7-[(2-methoxyphenyl)amino]-1-phenyl-1,6-naphthyrid in-2-one [00569] General procedure 15 was applied to 7-[(2-methoxyphenyl)amino]-1-phenyl-4- [2-(triisopropylsilyl)ethynyl]-1,6-naphthyridin-2-one (40.0 mg, 76.0 μmol) and potassium fluoride (24.0 mg, 0.411 mmol) in methanol (1.60 mL) and THF (1.60 mL). The resulting mixture was stirred for 4 h at room temperature and the crude residue was purified by reverse phase flash column chromatography eluting with methanol (10-50%) in water to yield the title compound as a yellow solid (15.0 mg, 53%). [00570] (ES, m/z): [M+H] ⁺ = 368.10. [00571] ¹ H-NMR (300 MHz, DMSO-d ₆ ) δ 8.69 (s, 1H), 8.63 (s, 1H), 7.73 (s, 1H), 7.71- 7.53 (m, 3H), 7.33-7.31 (d, J = 6.9 Hz,2H), 7.00-6.85 (m, 3H), 6.58 (s, 1H), 5.89 (s, 1H), 5.04(s, 1H), 3.72 (s, 3H). Example 4 2-Chloro-4-(phenylamino)pyrimidine-5-carboxamide [00572] A solution of 2,4-dichloropyrimidine-5-carboxamide (10.0 g, 52.1 mmol, 1.0 eq.), triethylamine (7.90 g, 78.1 mmol, 1.5 eq.), aniline (5.82 g, 62.5 mmol, 1.2 eq.) in THF (200 mL) was stirred overnight at room temperature. The reaction was then quenched by the addition of water (150 mL) and extracted with ethyl acetate (200 mL). The resulting mixture was washed with water (3 x 50 mL), dried (Na ₂ SO ₄ ) and concentrated under reduced pressure to yield the title compound as a white solid (12.0 g, 93%). 2-[(2-Methoxyphenyl)amino]-4-(phenylamino)pyrimidine-5-carbo xamide [00573] A solution of 2-chloro-4-(phenylamino)pyrimidine-5-carboxamide (12.0 g, 48.4 mmol, 1.0 eq.), o-anisidine (7.15 g, 58.1 mmol, 1.2 eq.) and N,N-diisopropylethylamine (9.38 g, 72.6 mmol, 1.5 eq.) in acetonitrile (200 mL) was stirred for 3 h at 110 °C. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The reaction was then quenched by the addition of water (500 mL) and the resulting solids were collected by filtration to yield the title compound as a yellow solid (15.0 g, 93%). 7-[(2-Methoxyphenyl)amino]-1-phenyl-3H-pyrimido[4,5-d][1,3]d iazine-2,4-dione [00574] A solution of 2-[(2-methoxyphenyl)amino]-4-(phenylamino)pyrimidine-5- carboxamide (10.0 g, 29.8 mmol, 1.0 eq.), CDI (14.5 g, 89.6 mmol, 3.0 eq.) and potassium carbonate (8.24 g, 59.7 mmol, 2.0 eq.) in THF was stirred for 2 h at room temperature before being concentrated under reduced pressure. The resulting material was diluted with water (500 mL) and the solids were collected by filtration to yield the title compound as an off-white solid (9.00 g, 46%). 4-Chloro-7-[(2-methoxyphenyl)amino]-1-phenylpyrimido[4,5-d][ 1,3]diazin-2-one [00575] A solution of 7-[(2-methoxyphenyl)amino]-1-phenyl-3H-pyrimido[4,5- d][1,3]diazine-2,4-dione (2.00 g, 5.53 mmol, 1.0 eq.) in acetonitirile, N,N-diisopropylethylamine (10 mL) and phosphorus(V) oxychloride (8.0 mL, 85.8 mmol, 16 eq.) was stirred for 30 min at 80 °C. The resulting mixture was concentrated under reduced pressure. The pH of the solution was adjusted to 8 with aqueous ammonia and the solids were collected by filtration to yield the title compound as a yellow green solid (2.00 g, 95%). 7-[(2-Methoxyphenyl)amino]-1-phenyl-4-[2-(triisopropylsilyl) ethynyl]pyrimido[4,5- d][1,3]diazin-2-one [00576] General procedure 9 was applied to 4-chloro-7-[(2-methoxyphenyl)amino]-1- phenylpyrimido[4,5-d][1,3]diazin-2-one (1.50 g, 3.95 mmol), triisopropylsilylacetylene (1.44 mg, 7.89 mmol), copper(I) iodide (75.5 mg, 0.395 mmol), bis(triphenylphosphine)palladium(II) dichloride (277mg, 0.395 mmol), N,N-diisopropylethylamine (1.52 g, 11.8 mmol) in DMF. The crude product was purified by reverse phase HPLC eluting with acetonitrile (20-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (1.20 g, 58%). 4-Ethynyl-7-[(2-methoxyphenyl)amino]-1-phenylpyrimido[4,5-d] [1,3]diazin-2-one [00577] A solution of 7-[(2-methoxyphenyl)amino]-1-phenyl-4-[2- (triisopropylsilyl)ethynyl]pyrimido[4,5-d][1,3]diazin-2-one (100 mg, 0.190 mmol) and ammonium fluoride (141 mg, 3.80 mmol) in THF (2.0 mL) and water (20 uL) was stirred for 20 min at room temperature. The crude product was purified by reverse phase HPLC eluting with acetonitrile (20-100%) in water (0.05% formic acid) to yield the title compound as a brown solid (15.0 mg, 21%). [00578] (ES, m/z): [M+H] ⁺ = 370 [00579] ¹ H-NMR (300 Hz, CDCl ₃ ) δ 9.01 (s, 1H), 8.40 (s, 1H), 7.84-7.56 (m, 4H), 7.46 (t, J = 6.5 Hz, 2H), 6.98 (t, J = 8.3 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 6.52 (t, J = 8.5 Hz, 2H), 3.90 (s, 3H), 3.80 (s, 1H). Example 5 2-((2-Methoxyphenyl)amino)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3- d]pyrimidin-7(8H)-one [00580] General procedure 13 was applied to 2-(methylsulfonyl)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-one (250 mg, 0.52 mmol) with aniline (64 mg, 0.68 mmol), trifluoroacetic acid (60 mg, 0.52 mmol) and 2-butanol (2.0 mL). The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (10-100%) in water (0.1% NH ₄ HCO ₃ ) to yield the title compound as a yellow solid (150 mg, 55%) [00581] (ES, m/z): [M+H] ⁺ = 495.3 5-Ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]py rimidin-7(8H)-one [00582] General procedure 15 was applied to 2-((2-methoxyphenyl)amino)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido [2,3-d]pyrimidin-7(8H)-one (150 mg, 0.286 mmol), potassium fluoride (83.0 mg, 1.43 mmol), methanol (10.0 mL) and water (1.0 mL). The crude material was purified by reverse phase flash column chromatography eluting with acetonitrile (10- 100%) in water (0.1% NH ₄ HCO ₃ ) then lyophilized to yield the title compound as a yellow solid (30.4 mg, 28%). [00583] (ES, m/z): [M+H] ⁺ = 339.1 [00584] ¹ H-NMR (300 MHz, DMSO-d ₆ ) δ 10.17 (s, 1H), 8.84 (s, 1H), 7.62-7.58 (t, J = 6.0 Hz, 3H), 7.38-7.35(dd, J = 9.0 Hz, 2H), 7.29-7.26 (d, J = 9.0 Hz, 2H), 6.99-6.94 (t, J = 7.5 Hz, 2H), 6.87-6.85 (1H, d, J = 6.0 Hz, 1H), 6.69 (s, 1H), 5.13 (s, 1H). Example 6 4-(4-Nitrophenyl)morpholine [00585] General procedure 11 was applied to 4-fluoro-1-nitrobenzene (1.55 g, 14.6 mmol) with morpholine (1.27 mL, 14.6 mmol) and potassium carbonate (3.30 g, 21.9 mmol) in DMSO (14.6 mL). The title compound, a bright yellow solid, was carried forward without further purification (2.29 g, 11.0 mmol, 75%). [00586] (ES, m/z): [M+H] ⁺ = 209.1 4-Morpholinoaniline [00587] General procedure 12 was applied to 4-(4-nitrophenyl)morpholine (1.50 g, 7.20 mmol) with palladium on carbon 5 wt. % (380 mg, 0.360 mmol) in ethanol (36 mL). The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound as a purple oil (1.28 g, 7.20 mmol, 100%). 2-((4-Morpholinophenyl)amino)-8-phenyl-5-((triisopropylsilyl )ethynyl)pyrido[2,3- d]pyrimidin-7(8H)-one [00588] General procedure 13 was applied to 2-(methylsulfonyl)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-one (500 mg, 1.04 mmol) with 4- morpholinoaniline (194 mg, 1.09 mmol) and trifluoroacetic acid (80.0 μL, 1.09 mmol) in acetonitrile (10 mL). The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound as an orange solid (186 mg, 0.320 mmol, 31%). [00589] (ES, m/z): [M+H] ⁺ = 580.5 5-Ethynyl-2-((4-morpholinophenyl)amino)-8-phenylpyrido[2,3-d ]pyrimidin-7(8H)-one [00590] General procedure 15 was applied to 2-((4-morpholinophenyl)amino)-8- phenyl-5-((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin- 7(8H)-one (113 mg, 0.190 mmol) with potassium fluoride (226 mg, 3.90 mmol) in DMF (2.0 mL) and methanol (2.0 mL). The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound as a red solid (31.4 mg, 74.1 μmol, 39%). [00591] (ES, m/z): [M+H] ⁺ = 424.3 [00592] ¹ H NMR (500 MHz, DMSO-d ₆ ) δ 10.07 (s, 1H), 8.79 (s, 1H), 7.60 (d, J = 7.2 Hz, 3H), 7.41 – 7.29 (m, 2H), 7.12 (d, J = 8.1 Hz, 2H), 6.64 (s, 1H), 6.53 (d, J = 7.6 Hz, 2H), 5.13 (s, 1H), 3.72 (dd, J = 5.8, 3.8 Hz, 4H), 2.96 (s, 4H). Example 7 3-Methoxy-N-methyl-4-nitroaniline [00593] General procedure 11 was applied to 5-fluoro-2-nitroanisole (1.50 g, 8.77 mmol) with methyl amine hydrochloride (1.20 g, 17.5 mmol) and potassium carbonate (2.40 g, 17.5 mmol) in DMSO (6.0 mL). The title compound, a bright yellow solid, was carried forward without further purification (1.25 g, 6.89 mmol, 79%). [00594] (ES, m/z): [M+H] ⁺ = 183.0 2-Chloro-N-(3-methoxy-4-nitrophenyl)-N-methylacetamide [00595] A solution of 3-methoxy-N-methyl-4-nitroaniline (1.42 g, 7.80 mmol, 1.0 eq.) and chloroacetyl chloride (740 μL, 9.36 mmol, 1.2 eq.) in ethyl acetate (16 mL, 0.5 M) was stirred at 70 °C for 1 h, then cooled to room temperature. Upon the addition of 40-60 petroleum ether, the precipitate formed was collected by vacuum filtration to yield the title compound (1.29 g, 4.99 mmol, 64%). [00596] (ES, m/z): [M+H] ⁺ = 259.1 2-(Dimethylamino)-N-(3-methoxy-4-nitrophenyl)-N-methylacetam ide [00597] A solution of 2-chloro-N-(3-methoxy-4-nitrophenyl)-N-methylacetamide (1.00 g, 3.87 mmol, 1.0 eq.), dimethylamine (13.5 mL, 13.5 mmol, 3.5 eq.) and potassium carbonate (1.87 g, 13.5 mmol, 3.5 eq.) in THF (77 mL, 0.05 M) and water (38 mL, 0.1 M) was stirred at room temperature overnight. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (30 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried (MgSO ₄ ) and concentrated under reduced pressure. The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound (601 mg, 2.25 mmol, 58%). [00598] (ES, m/z): [M+H] ⁺ = 268.2 N-(4-Amino-3-methoxyphenyl)-2-(dimethylamino)-N-methylacetam ide [00599] General procedure 12 was applied to 2-(dimethylamino)-N-(3-methoxy-4- nitrophenyl)-N-methylacetamide (600 mg, 2.24 mmol) with palladium on carbon 5 wt. % (239 mg, 0.224 mmol) in ethanol (8.1.0 mL) and acetic acid (0.90 mL). The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound as a purple oil (587 mg, 2.83 mmol, 100%). 2-(Dimethylamino)-N-(3-methoxy-4-((7-oxo-8-phenyl-5-((triiso propylsilyl)ethynyl)-7,8- dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)-N-methylace tamide [00600] General procedure 13 was applied to 2-(methylsulfonyl)-8-phenyl-5- ((triisopropylsilyl)ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-one (500 mg, 1.04 mmol) with N-(4- amino-3-methoxyphenyl)-2-(dimethylamino)-N-methylacetamide (226 mg, 1.09 mmol) and trifluoroacetic acid (80.0 μL, 1.09 mmol) in acetonitrile (10 mL). The crude material was purified by flash column chromatography eluting with methanol (0-20%) in dichloromethane to yield the title compound as an orange solid (178 mg, 0.278 mmol, 27%). [00601] (ES, m/z): [M+H] ⁺ = 639.5 2-(Dimethylamino)-N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydr opyrido[2,3-d]pyrimidin- 2-yl)amino)-3-methoxyphenyl)-N-methylacetamide